Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Health Care Guideline:
Management of Labor
Third Edition May 2009
I ICSI NSTITUTE FOR C LINICAL S YSTEMS I MPROVEMENT
The information contained in this ICSI Health Care Guideline is intended primarily for health profes-sionals and the following expert audiences:
• physicians,nurses,andotherhealthcareprofessionalandproviderorganizations;
• healthplans,healthsystems,healthcareorganizations,hospitalsand integratedhealthcaredeliverysystems;
• healthcareteachinginstitutions;
• healthcareinformationtechnologydepartments;
• medicalspecialtyandprofessionalsocieties;
• researchers;
• federal,stateandlocalgovernmenthealthcarepolicymakersandspecialists;and
• employeebenefitmanagers.
ThisICSIHealthCareGuidelineshouldnotbeconstruedasmedicaladviceormedicalopinionrelatedtoanyspecificfactsorcircumstances.Ifyouarenotoneoftheexpertaudienceslistedaboveyouareurgedtoconsultahealthcareprofessionalregardingyourownsituationandanyspecificmedicalquestionsyoumayhave.Inaddition,youshouldseekassistancefromahealthcareprofessionalininterpretingthisICSIHealthCareGuidelineandapplyingitinyourindividualcase.
ThisICSIHealthCareGuidelineisdesignedtoassistcliniciansbyprovidingananalyticalframeworkfortheevaluationandtreatmentofpatients,andisnotintendedeithertoreplaceaclinician'sjudgmentortoestablishaprotocolforallpatientswithaparticularcondition.AnICSIHealthCareGuidelinerarelywillestablishtheonlyapproachtoaproblem.
CopiesofthisICSIHealthCareGuidelinemaybedistributedbyanyorganizationtotheorganization'semployeesbut,exceptasprovidedbelow,maynotbedistributedoutsideoftheorganizationwithoutthepriorwrittenconsentoftheInstituteforClinicalSystemsImprovement,Inc.Iftheorganizationisalegallyconstitutedmedicalgroup,theICSIHealthCareGuidelinemaybeusedbythemedicalgroupin any of the following ways:
• copiesmaybeprovidedtoanyoneinvolvedinthemedicalgroup'sprocessfordevelopingandimplementingclinicalguidelines;
• the ICSI Health Care Guideline may be adopted or adapted for use within the medical group only,providedthatICSIreceivesappropriateattributiononallwrittenorelectronicdocuments;and
• copiesmaybeprovidedtopatientsandtheclinicianswhomanagetheircare,iftheICSIHealthCareGuidelineisincorporatedintothemedicalgroup'sclinicalguidelineprogram.
AllothercopyrightrightsinthisICSIHealthCareGuidelinearereservedbytheInstituteforClinicalSystemsImprovement.TheInstituteforClinicalSystemsImprovementassumesnoliabilityforanyadaptationsorrevisionsormodificationsmadetothisICSIHealthCareGuideline.
Health Care Guideline:
Management of Labor
www.icsi.org
I ICSI NSTITUTE FOR C LINICAL S YSTEMS I MPROVEMENT
Copyright © 2009 by Institute for Clinical Systems Improvement 1
A = Annotation
Third Edition May 2009
Is fetal heart rate a concern?
16
Pregnant patient > 20 weeks with symptoms
of labor
1
Triage for symptomsof labor
2
A
< 37 weeks?
3
See Management of Signs/Symptoms of
Preterm Laboralgorithm and
annotations
4
yes
Is patient in labor?
5
A
no
• Patient education for reassurance• Observe and re-evaluate• Consider labor induction if appropriate
6
noPrevious uterine
incision?
9
yes
Subsequent labor?
7
yes
Intrapartum care• Cervical exam• Supportive care• Adequate pain relief• Perform amniotomy if needed unless contraindicated• Monitoring of fetal heart rate• Nurse ausculatory monitoring or continuous EFM-ext
no
See VBAC algorithmand annotations
10
yes
11
A
Any concerns or complications?
12
A
Management of third stage of labor
no
See Intrapartum FetalHeart Rate Management
algorithm and annotations
See Management of Labor Dystocia algorithm and
annotations
18
Other• Out of guideline
yes
no
Out of guideline
8
Normal vaginal delivery
13 14
A
no
17
Is progression of labor a concern?
no
15
19
yes yes
Institute for Clinical Systems Improvement
www.icsi.org
2
Management of Signs/Symptoms of Preterm Labor (PTL) Algorithm
Management of Labor Third Edition/May 2009
This algorithm applies to singleton pregnancies only.
Patient and fetus both medically
stable?
Is there a critical event?
21
23
no
yes
Cervix > 2 cm dilated, > 80%
effaced, contractions 4/20 or 6/60?
25
Ultrasound cervical length < 2.5 cm or fFn
positive?
26
no
yes
no
yes
no
Obstetric/medicalconsultation as indicated;
treat per standard emergency medical and obstetric
procedures
22
See Management of Critical Event algorithm
24
Assessment of patient with signs/symptoms of possible PTL
20
A
Assessment includes:
• Sterile speculum exam - Fetal fibronectin testing - Consider GBS, wet prep for bacterial vaginosis - GC, chlamydia• Digital cervical exam• Transvaginal ultrasound for cervical length (if available)• Ultrasound for growth, fluid, placenta• Assess contraction patterns• Assess fetal well-being• Urinalysis and urine culture
20
See ICSI Routine Prenatal Care
guideline
28
Critical events:
• Cervix 5+ cm dilated• pPROM• Vaginal bleeding• Chorioamnionitis suspected
23
Cervical change?
29
See Management of Critical Event algorithm
30
yes
• Consider antenatal cortiosteroids• Dismiss and schedule weekly follow-up - Digital exam to assess cervix - Repeat fFn until 33 weeks plus 6 days
31
Monitor for minimum2 hours for cervical
changes
27
no
yes
Institute for Clinical Systems Improvement
www.icsi.org
3
Management of Labor Third Edition/May 2009
A = Annotation
Management of Critical Event Algorithm
Possibly initiate tocolytics, antenatal corticosteroids and antibiotic group B streptococcus (GBS) prophylaxis
Deliver for:• Fetal distress• Chorioamnionitis• Active labor• 34 weeks PROM• Other obstetrical indicators
Cervix 5+ cm dilated?
Patient has critical event
33
Initial dose antenatal corticosteroids STAT, IV
antibiotics for groupB streptococcus (GBS) and
plan for delivery
yes
34
A
Safe to transfer or transport mother
before birth?
35
Prepare for preterm delivery/neonatal
transport
36
no
Chorioamnionitis suspected?
38
no
Broad spectrum antibiotics
yes
39
Plan for delivery
40
yes
• Stabilize on tocolytics• Transfer mother to appropriate level of care if possible
41
Antenatal corticosteroids23-34 weeks
42
A
Sonogram for:• Amniotic fluid index (AFI)• Presentation/placentation• Follow-up level II as indicated
43
Sonogram detects gross
anomaly?
44
Fetal anomaly compatible with
life?
45
no
47
ROM?
48
Vaginal pool + amnio at 32+ weeks for fetal lung
maturity (FLM)
yes
49
Vaginal bleeding?
50
no
Management of preterm labor with bleeding
yes
51
A
no
Fetal lung maturity (FLM) study
positive?
53
Preterm delivery
55
yes
A
A
32
A
yes no Await spontaneous labor
46
yes
Deliver for:• Disseminated intravascular coagulation (DIC)• FLM• Fetal distress• Nonreassuring FHT• Significant bleeding
52
A
54
no
A
• Stabilize on tocolytics• Transfer mother to appropriate level of care if possible
37
A
no
Institute for Clinical Systems Improvement
www.icsi.org
4
Management of Labor Third Edition/May 2009
Vaginal Birth After Caesarean (VBAC) Algorithm
A = AnnotationPatient in active labor with previous uterine
incision
56
Special considerations of labor management
57
A
Vaginal birth appropriate?
58
Repeat Caesarean delivery
no
Normal labor?62
59
yes
Complicated labor management
no
60
A
Vaginal birth
yes
61
• Availability of Caesarean delivery team• Review prior op report regarding previous uterine incision• EFM and intermittent auscultation• Use of foley bulb catheter for cervical ripening• Epidural anesthesia
57
Signs and symptoms of uterine rupture:• Fetal distress• Uterine pain• Hemorrhage• Palpation of fetal parts• Loss of contraction• Recession of presenting part• Fetal death
60
Institute for Clinical Systems Improvement
www.icsi.org
5
Management of Labor Third Edition/May 2009
Management of Labor Dystocia Algorithm
Labor dystocia diagnosis
Stage I labor Stage II labor
64 70
Fetal head descent
> 1 cm/hour?
71
A
Normal vaginal delivery
72
yes
< 1 cm dilation for 2 consecutive
hours?
65
Management of protracted labor• Evaluate potential causesConsider: - IV fluids - Amniotomy - Decrease anesthesia - Oxytocin augmentation - IUPC - OB/surgery consult
66
Adequate labor for 2-4 hours with
cervical change?
67
yes
Caesarean delivery
69
yes
Management of protracted labor• Evaluation of maternal and fetal position• Oxytocin augmentation• Allow contractions to move fetus• Decrease anesthesia• Evaluate fluid balance• Consider assisted delivery• Consider OB/surgery consult
73
A
no
Is the head descending?
74
yes
Assistedvaginal delivery
indicated?
75
A
no
no
Assisted vaginal delivery
yes76
no
no
A
Arrest of labor
68
63
A A
A
Institute for Clinical Systems Improvement
www.icsi.org
6
Management of Labor Third Edition/May 2009
Intrapartum Fetal Heart Rate (FHR) Management Algorithm
A = Annotation
Assessment and remedial techniques
Further FHR assessment predictive of normal acid-base
status?
FHR pattern is predictive of normal
acid-base status?
80
82
no
FHR pattern predictive of
normal acid-base status now?
83
Vaginal delivery imminent?
no
84
no
86
A
A
Expedited vaginal delivery
yes
85
Consider amnioinfusion for oligohydramnios and severe
variable or prolonged decelerations
79
Continuous EFM-ext orEFM-int (if needed)
78
Concern about fetal heart rate
77
See algorithm #12, "Any concerns or complications?"
yes
Emergent delivery
87
A
81
yes
yes
A
no
A
Institute for Clinical Systems Improvement
www.icsi.org
7
Management of Labor Third Edition/May 2009
Algorithms and Annotations ....................................................................................... 1-29Algorithm (Main) ............................................................................................................... 1Algorithm (Management of Signs/Symptoms of Preterm Labor [PTL]) ........................... 2Algorithm (Management of Critical Event) ....................................................................... 3Algorithm (Vaginal Birth After Caesarean [VBAC]) ......................................................... 4Algorithm (Management of Labor Dystocia) ..................................................................... 5Algorithm (Intrapartum Fetal Heart Rate [FHR] Management) ........................................ 6Foreword
Scope and Target Population ......................................................................................... 8Clinical Highlights and Recommendations .................................................................. 8Priority Aims ................................................................................................................. 9Related ICSI Scientific Documents .............................................................................. 9Disclosure of Potential Conflict of Interest ................................................................... 9Introduction to ICSI Document Development .............................................................. 9Description of Evidence Grading................................................................................ 10Abbreviations .............................................................................................................. 10
Annotations ..................................................................................................................11-27Annotations (Main) .................................................................................................11-14Annotations (Management of Signs/Symptoms of Preterm Labor [PTL]) ............ 15-16Annotations (Management of Critical Event) ........................................................ 16-20Annotations (Vaginal Birth After Caesarean [VBAC]) ......................................... 20-22Annotations (Management of Labor Dystocia) ..................................................... 22-24Annotations (Intrapartum Fetal Heart Rate [FHR] Management) ......................... 24-27
Appendix A – Patient Education Handout ................................................................... 28-29Supporting Evidence.................................................................................................... 30-51
Brief Description of Evidence Grading ............................................................................ 31References ...................................................................................................................32-39Conclusion Grading Worksheets .................................................................................40-51
Conclusion Grading Worksheet A – Annotation #20 (Bacterial Vaginosis) ..........40-43Conclusion Grading Worksheet B – Annotation #66 (Management of Protracted Labor) ..................................................................44-51
Support for Implementation ..................................................................................... 52-60Priority Aims and Suggested Measures ............................................................................ 53
Measurement Specifications .................................................................................. 54-58Knowledge Resources ...................................................................................................... 59Resources Available.......................................................................................................... 60
Table of Contents
Work Group LeaderDouglas Creedon, MDOB/Gyn, Mayo ClinicWork Group MembersFamily MedicineLeslie Atwood, MDAllina Medical ClinicLori Bates, MD Mayo ClinicDana-Rae Barr, MDHennepin County Medical CenterNurse MidwifeAnna Levin, CNMPark Nicollet Health ServicesCherida McCall, CNMHealthPartners Medical GroupRuth Wingeier, CNMCentraCareNursingBecky Walkes, RNMayo ClinicOB/GynDale Akkerman, MD Park Nicollet Health ServicesPerinatal MedicineLeslie Pratt, MDPark Nicollet Health ServicesFacilitatorsLinda Setterlund, MA, CPHQICSILynette Wheelock, RN, MSICSI
Institute for Clinical Systems Improvement
www.icsi.org
8
Foreword
Scope and Target PopulationAll women who present in labor.
Clinical Highlights and Recommendations• Confirm active labor before admitting to facility evidenced by:
- Spontaneous contractions at least 2 per 15 minutes, and two or more of the following:
• Complete effacement of cervix
• Cervical dilation greater than or equal to 3 cm
• Spontaneous rupturing of membranes (SROM)
(Annotation #5)
• Perform amniotomy early in labor if indicated as discussed in the guideline. (Annotation #11)
• Assure fetal well-being with either intermittent auscultation or continuous electronic fetal heart rate monitoring. (Annotation #11)
• Patient's level of risk should be assessed on presentation of active labor.
- Oligohydramnios
- Chronic and acute medical conditions of mother and/or fetus
(Annotation #12; Aim #4)
• Start appropriate treatment for the type of preterm labor involved as soon as possible after preterm labor is identified. Treatment should be based on specific symptoms, as well as gestational age and condition of the mother and fetus. (Annotation #20; Aim #1)
• Women with preterm labor at appropriate gestational age should receive a single course of antepartum steroids to promote fetal lung maturity. (Annotations #34, 42, 47; Aim #1)
• Conduct frequent cervical checks (cervical checks afford best opportunity to detect labor progress and prevent failure to progress). (Annotation #65)
• Augment with oxytocin to achieve adequate labor for two to four hours. (Annotation #66)
• If patient is in Stage II labor and is not making progress, initiate management of protraction disorders (positioning, fluid balance, oxytocin augmentation, OB/surgical consult). (Annotation #73; Aim #2)
• When necessary, initiate remedial techniques such as maternal position, cervical exam for cord prolapse, monitoring maternal blood pressure, assessment for uterine hyperstimulation, discontinuing oxytocics and amnioinfusion. (Annotation #82; Aim #5)
• Recognize and manage fetal heart rate abnormal patterns. (Annotation #80; Aim #6)
Management of Labor Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
9
Priority Aims 1. Increase the percentage of women with PTL and/or PTB who receive antenatal corticosteroids appro-
priately.
2. Prevent unnecessary protracted labor with use of Management of Labor Dystocia algorithm and annota-tions and its methods.
3. Increase the use of procedures that assist in progress to vaginal birth.
4. Increase the percentage of women who are assessed for risk status on entry to labor and delivery.
5. Increase the use of remedial techniques that resolve temporary abnormal fetal heart tracing in labor.
6. Perform an appropriate evaluation for persistent abnormal fetal heart rate tracing in labor before Caesarean.
Related ICSI Scientific DocumentsGuidelines
• Routine Prenatal Care
Disclosure of Potential Conflict of InterestICSI has adopted a policy of transparency, disclosing potential conflict and competing interests of all indi-viduals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee and Respiratory Steering Committee).
Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.
No work group members have potential conflicts of interest to disclose.
Introduction to ICSI Document DevelopmentThis document was developed and/or revised by a multidisciplinary work group utilizing a defined process for literature search and review, document development and revision, as well as obtaining input from and responding to ICSI members.
For a description of ICSI's development and revision process, please see the Development and Revision Process for Guidelines, Order Sets and Protocols at http://www.icsi.org.
Management of Labor Foreword Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
10
Evidence Grading SystemA. Primary Reports of New Data Collection:
Class A: Randomized, controlled trial
Class B: Cohort study
Class C: Non-randomized trial with concurrent or historical controls Case-control study Study of sensitivity and specificity of a diagnostic test Population-based descriptive study
Class D: Cross-sectional study Case series Case report
B. ReportsthatSynthesizeorReflectUponCollectionsofPrimaryReports:
Class M: Meta-analysis Systematic review Decision analysis Cost-effectiveness analysis
Class R: Consensus statement Consensus report Narrative review
Class X: Medical opinion
Citations are listed in the guideline utilizing the format of (Author, YYYY [report class]). A full explanation of ICSI's Evidence Grading System can be found at http://www.icsi.org.
Abbreviations Used in This GuidelinefFN fetal fibronectin
FHR fetal heart rate
FHT fetal heart tracing
FLM fetal lung maturity
GBS group B streptococcus
N, P, F nitrazine, pooling and ferning
PROM premature rupture of membranes
pPROM preterm premature rupture of membranes
PTL preterm labor
ROM rupture of membranes
VBAC vaginal birth after Caesarean
Management of Labor Foreword Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
11
Algorithm Annotations
The recommendations in this guideline are supported by large controlled studies. The guideline work group would prefer to refer to double-blind studies, but it is not feasible to blind a woman to whether she is having labor or delivery. It is unsafe to blind care providers to whether a woman has had a previous Caesarean delivery or not or previous labor and delivery complications. It is also unsafe to blind providers to whether persistent non-reassuring heart rate tracings have occurred. Given these limitations, the work group feels confident of the literature support for the recommendations within this guideline. Furthermore, these recommendations are consistent with the latest practice patterns published by the American College of Obstetricians and Gynecologists.
Management of Labor Main Algorithm Annotations
2. Triage for Symptoms of Labor Hospital and/or clinic triage for the labor patient will include these questions. Triage staff will assess general questions from OB experience. Some questions may require more details for assessment. Generally, the patient is encouraged to remain home as long as possible. The caregiver will manage any/all medical concerns according to accepted standards.
General Questions:
• Are you having contractions?
• Is this your first baby?
• Was your cervix dilated at least 2-3 cm on your last office visit?
• Did you have medical complications during your pregnancy? Get specifics.
• Are you at term? (What is your estimated date of conception?)
SpecificQuestions:
• Is your baby moving as usual?
- If no, advise go to hospital.
• Has your water broken?
- If yes, advise go to hospital.
• Are you bleeding?
- If yes, advise go to hospital.
• Are you having unbearable contractions?
- If yes, advise go to hospital.
When a patient presents to hospital and assessment shows the patient is NOT in labor: Patient education will include signs to look for, changes to assess, and reassurance that she can come back to the hospital when changes occur. When the caregiver prefers to hold and observe the patient, a reassessment must be conducted prior to release from the hospital.
Management of Labor Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
12
5. Is Patient in Labor? Laborisdefinedas:
Spontaneous contractions at least 2 per 15 minutes and at least two of the following:
• Complete effacement of cervix
• Cervical dilation 3 cm or greater (cervical exam #1)
• Spontaneous rupturing of membrane (SROM)
Onlypatientswhomeetthisdefinitionoflaborshouldbeadmittedforcarefulmanagementoflabor.Careful assessment of presenting patients is critical.
Patients who are not in labor should receive education that includes signs to look for, changes to assess, and reassurance that they can come back to the hospital when changes occur. (See Appendix A, "Patient Educa-tion Handout.") A patient may be placed on "hold" status for observation. Hold patients require medical reassessment before leaving the hospital.
If the patient's cervix is dilated less than 3 cm and oxytocin is started, this should be considered induction of labor, NOT augmentation of labor (American College of Obstetricians and Gynecologists, The, Practice Bulletin, 2003 [R]).
11. Intrapartum Care See ICSI Admission for Routine Labor Order Set.
Characteristics of care for a patient at time of admission to labor and delivery include:
• Chart evaluation
• Cervical exam #2
• Appropriate supportive care/comfort measures as per individual provider. May include, but are not limited to PO fluids, fluid balance maintenance, position changes, back rubs, music, ambulation, and tub bath/shower. Management of labor using patient care measures and comfort measures is supported. Documentation of progress of labor using a graphic medium is helpful to patient and staff (McNiven, 1992 [D]; Radin, 1993 [C]).
• Adequate pain relief. This includes parenteral analgesics, e.g., nalbuphine hydrochloride (such as Nubain), butorphanol tartrate (such as Stadol) or hydroxyzine hydrochloride (such as Vistaril) or epidural or intrathecal narcotics for patients in active progressing labor (continued dilation of the cervix) (Clark, 1998 [A]; Halpern, 1998 [M]; Rogers, 1999 [C]).
• Documentation of progress of labor using a graphic medium (partogram) is started on admission.
• Monitoring of fetal heart rate. (See Intrapartum Fetal Heart Rate [FHR] Management algorithm and annotations).
• Amniotomy unless contraindicated. Amniotomy should be done early in labor unless spontaneous rupture has occurred or contraindications are present. Early amniotomy has been shown to be asso-ciated with a decrease in duration of labor and is part of the failure to progress protocol (Brisson-Carroll, 1996 [M]; Fraser, 1993 [A]; Fraser, 2000a [M]; Garite, 1993 [A]).
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
13
Contraindications for amniotomy include:
• Presentation unknown, floating or unstable
• Cervix dilated less than 3 cm
• Patient refuses
Continuous Electronic Fetal Heart Rate Monitoring or Intermittent AuscultationThe established purpose of fetal heart rate (FHR) monitoring is to identify fetal hypoxemia and acidemia so timely intervention can prevent fetal morbidity and mortality. This is based on the rationale that FHR patterns are indirect markers for hypoxemia and acidemia since the central nervous system controls heart rate. Virtually all obstetrical organizations advise monitoring the FHR during labor, although no trials have compared FHR monitoring versus no monitoring (Freeman, 2002 [R]). The most common methods of FHR monitoring are continuous electronic FHR monitoring (EFM) and intermittent auscultation. EFM can be done with an external cardiotocography monitor or an internal (scalp) lead and can provide a continuous assessment of FHR variability and any changes from the baseline heart rate (see table of interpreting FHR monitoring). Intermittent auscultation consists of auscultating FHR with either a DeLee stethoscope or a Doppler probe for 30 seconds immediately following a contraction. This monitoring must be performed every 30 minutes during Stage I of labor and every 15 minutes during Stage II (American College of Obestetrics and Gynetcolgists, The, 2005 [R]).
Analysis of data from randomized trials comparing these two techniques shows:
• No difference in the rate of intrapartum fetal death rate (approximately 0.5 per 1,000 births with either approach)
• No difference in APGAR scores and NICU admissions
• Neither approach has resulted in a reduction in cerebral palsy or incidence of infant neurologic impairment
Several advantages to EFM have been demonstrated, including a reduction in neonatal seizures (Alfirevic, 2006 [M]) and better prediction of fetal acidemia at birth (Vintzileos, 1993 [A]; Vintzileos, 1995 [M]). One disadvantage to EFM is that it leads to higher assisted deliveries and Caesarean birth without an associated neonatal benefit (Alfirevic, 2006 [M]). Compared to intermittent auscultation, EFM is associated with a twofold increase in Caesarean delivery rate for non-reassuring FHR patterns.
12. Any Concerns or Complications?Risk assessment should be performed on all patients in active labor and is the responsibility of all members of the health care team. This includes, but is not limited to nurses, midwives and physicians. Patient is in active labor. (See Annotation #5, "Is Patient in Labor?" for specific definition.)
Initial assessments on entry into labor and delivery area:
• Fetal heart rate assessment (Cheyne, 2003 [A]; Impey, 2003 [A])
• Patient assessment
• Prenatal risk review
• Risk in labor assessment
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
14
High-risk situations may include any of the following conditions:
• Abnormal fetal heart rate (see Intrapartum Fetal Heart Rate [FHR] Monitoring algorithm and anno-tations)
• Situations that involve arrest or protraction disorders (see Management of Labor Dystocia algorithm and annotations)
• Bleeding
• Breech presentation
• Dysfunctional labor
• Fetal congenital heart disease
• Intrauterine growth retardation
• Maternal congenital heart disease
• Maternal diabetes or gestational diabetes
• Maternal hypertension
• Maternal lupus
• Multiple gestation
• Oligohydramnios
• Other serious chronic and acute medical conditions of mother and/or fetus
• Oxytocin use
• Postdate pregnancy (greater than or equal to 42 weeks, per physician discretion)
• Thick meconium
For the evaluation of fetal heart rate in high-risk labor see (Haverkamp, 1976 [A]; Renou, 1976 [A]; Vintzi-leos, 1993 [A]; Vintzileos, 1995 [M]).
14. Management of Third Stage of LaborActive Management of the third stage of labor should be offered to women since it reduces the incidence of postpartum hemorrhage due to uterine atony. Active management of the third stage of labor consists of interventions designed to facilitate the delivery of the placenta by increasing uterine contractions and to prevent postpartum hemorrhage by averting uterine atony. The usual components include:
• administration of uterotonic agents,
• controlled cord traction, and
• uterine massage after delivery of the placenta, as appropriate.
(Elbourne, 2003 [M]; International Confederation of Midwives [ICM], 2004 [R])
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
15
Management of Signs/Symptoms of Preterm Labor (PTL) Algorithm Annotations
20. Assessment of Patient with Signs/Symptoms of Possible Preterm LaborBe certain intervention is appropriate, including certainty of gestational age. A sonogram should be consid-ered if one has not been done.
A thorough medical evaluation should include the following:
• Perform a sterile speculum exam to visualize the cervix to:
- identify any source of bleeding or cervical or vaginal pathology or trauma
- estimate dilation and effacement of the cervix and look for pooling of amniotic fluid as a sign of ruptured membranes
- obtain samples for fetal fibronectin testing (fFN)*, consider samples for gonorrhea, chlamydia, (Andrews, 2000 [C]) wet prep for bacterial vaginosis**, group B streptococcus (GBS), and a sample for detecting amniotic fluid with either ferning, nitrazine paper, or Amnisure
* Perform fetal fibronectin testing (fFN), if patient is between 24 and 34 weeks gestation, and cervix less than 3 cm dilated. Patients with a negative test can expect pregnancy to continue for 7-14 days.
** Consider screening high-risk women with a history of at least one preterm delivery for bacte-rial vaginosis. If positive, treatment should include oral metronidazole. Treatment of bacterial vaginosis infection in pregnant women at high risk for preterm delivery by traditional seven-day courses of therapy early in pregnancy appears to reduce preterm delivery. [Conclusion Grade II: See Conclusion Grading Worksheet A – Annotation #20 (Bacterial Vaginosis)] The evidence regarding treatment of low-risk, pregnant women with asymptomatic bacterial vaginosis is limited by use of inadequate therapy in the available studies. [Conclusion Grade Not Assignable: See Conclusion Grading Worksheet A – Annotation #20 (Bacterial Vaginosis)]
(Carey, 2000 [A]; Leitich, 2003 [M]; McDonald, 1997 [A]; McGregor, 1995 [C]; Morales, 1994 [A]; Tebes, 2003 [R])
• Perform digital cervical exam if membranes are intact and there is no vaginal bleeding. If ruptured, digital exams increase the risk of infection.
• Obtain transvaginal sonogram (TVS) for cervical length for monitoring of patients with sign/symp-toms of preterm labor and early cervical change. Cervical length of less than or equal to 25 mm or a rapidly thinning cervix correlate with increased preterm birth rates (Vendittelli, 2000 [R]).
• Perform bedside ultrasound (if feasible) to assess:
- Presentation
- Amniotic fluid index
- Biophysical profile
- Estimated fetal weight
• Assess contraction pattern
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
16
• Assess fetal heart rate pattern and fetal well-being
• Obtain urinalysis, urine culture and urine drug screen (if appropriate)
Consider non-intervention near-term if gestational age is well documented. Do not inhibit labor where there is fetal or maternal jeopardy, fetal malformation or death.
Evidence indicates prophylaxis with progesterone may decrease the reoccurrence of preterm labor in women with a history of one or more preterm births (da Fonseca, 2003 [A]; Meis, 2003 [A]). See ICSI Routine Prenatal guideline.
Fish oil supplementation has not been found to be helpful in preventing preterm labor. One analysis of six clinical trials found an increase in intracranial hemorrhage among infants whose mothers took fish oil supplements during pregnancy compared to those who took olive oil (Olsen, 2000 [A]).
DefinitionofPretermLabor:
• Labor occurring after 20 and before 37 completed weeks plus
• Clinically documented uterine contractions (4/20 minutes or 6/60 minutes) plus
• Ruptured membranes or
• Intact membranes and cervical dilation greater than 2 cm or
• Intact membranes and cervical effacement greater than 80% or
• Intact membranes and cervical change during observation. These can be measured by changes in dilation or effacement, or by changes in cervical length measured clinically or by ultrasound.
Management of Critical Event Algorithm Annotations
34. Initial Dose Antenatal Corticosteroids STAT, IV Antibiotics for Group B Streptococcus (GBS), and Plan for DeliveryPlease refer to Annotation #47, "Possibly Initiate Tocolytics, Antenatal Corticosteroids and Antibiotic Group B Strepcoccus (GBS) Prophylaxis," for information on dosing of other corticosteroids.
37. Stabilize on Tocolytics/Transfer Mother to Appropriate Level of Care if PossibleSeveral medications are available for the inhibition of preterm labor (tocolysis). These drugs have different routes of administration, dose schedules, safety profiles, contraindications, and fetal and maternal side effects (Simhan, 2007 [R]). Although several medications can prevent delivery for 24-48 hours (allowing time for the administration and beneficial effects of corticosteroid therapy), the longer-term efficacy of all tocolytics is poor (Gyetvai, 1999 [M]).
Magnesium sulfate
Review of the literature does not support the efficacy of magnesium sulfate as a tocolytic. The largest random-ized, placebo-controlled trial showed no benefit over placebo (Cox, 1990 [A]). A more recent meta-analysis of 11 studies showed no benefit regarding the risk of preterm birth (less than 37 weeks) or very preterm birth (less than 34 weeks). Moreover, in seven of the trials analyzed, the risk of perinatal mortality was increased for infants exposed to magnesium sulfate (Crowther, 2002 [M]; Grimes, 2006 [R]; Mittendorf, 2002 [R]). The work group does not recommend the use of this medication for this indication.
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
17
A series of recent randomized controlled trials (Doyle, 2009 [M]; Marret, 2008 [A]; Rouse, 2008 [A]) evaluated the administration of magnesium sulfate in clinical situations when preterm delivery is regarded as imminent. Review of these trials has suggested magnesium sulfate does not work well as a tocolytic, but does provide a reduction in both the frequency and severity of cerebral palsy for those infants surviving the immediate intrapartum time frame. The following points from these studies are important to note:
• Very preterm birth (less than 34 weeks) and very low birth weight (less than 1,500 g) are principal risk factors for cerebral palsy, making up between 17% to 32% of all cases of cerebral palsy.
• Evidence from population-based registries shows the prevalence of cerebral palsy is rising in very low birth weight infants.
• Recent retrospective studies confirm that the increasing prevalence of cerebral palsy is from higher rates in preterm, not term, infants.
The term neuroprotection is used to describe the possible indication for magnesium sulfate in these clinical situations. Although the results from the relevant studies are intriguing, one of the principal researchers for two of these studies suggests it is not yet time to recommend the routine use of magnesium sulfate for neuroprotective benefits in any circumstance of preterm labor (Crowther, 2002 [M]):
A meta-analysis involving individual patient data from the various trials might help to answer these ques-tions, better guide clinical-practice recommendations, and frame future research. Information from long-term follow-up of children whose mothers received antenatal magnesium sulfate also is needed to clarify the neuroprotective role of this therapy before preterm birth (Stanley, 2008 [R]).
Calcium channel blockers
Nifedipine is the drug most commonly employed from this class of medications for tocolysis. No placebo-controlled trials have evaluated the drug for this indication, but comparative trials have demonstrated the efficacy and safety of the drug (King, 2003 [M]; Papatsonis, 1997 [A]).
Beta-adrenergic-receptor agonists
Terbutaline is one of the commonly employed drugs from this class of medications for tocolysis. Avail-able studies show a prolongation of pregnancy similar to the results of calcium channel blockers, but no significant reduction in perinatal morbidity or mortality (Anotayanouth, 2004 [M]). However, the absence of such findings may be a result of the sample size in some of the trials analyzed.
Cyclooxygenase inhibitors
Indomethacin is the drug most commonly employed from this class of medications for tocolysis. A meta-analysis of three comparative trials with other classes of tocolytics showed a reduction of preterm births (< 37 week) (King, 2005 [M]). Indomethacin should only be used at less than 32 weeks gestation and only for 48 hours maximum to allow for the administration of antenatal corticosteroids (Doyle, 2005 [M]; Loe, 2005 [M]).
Maternal transfer to prevent the need for premature neonatal transfer reduces preterm neonatal morbidity and mortality. Very low birthweight infants (less than 1,500 grams) inborn to Level III perinatal centers have lower mortality, reduced incidence of Grade III and Grade IV intraventricular hemorrhage, and lower sensorineural disability rates than outborn infants (Menard, 1998 [C]; Towers, 2000 [C]; Yeast, 1998 [C]).
39. Broad Spectrum AntibioticsBroad-spectrum antibiotic coverage appears to lengthen the latency from preterm premature rupture of membranes (pPROM) until delivery and/or chorioamnionitis. Antibiotic therapy reduces maternal and neonatal morbidity in women with pPROM. There is no consensus on the choice of antibiotic or dose. A
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
18
combination of ampicillin and erythromycin appears promising (Bar, 2000 [C]; Edwards, 2000 [C]; Kenyon, 2000 [M]; Mercer, 1997 [A]).
41. Stabilize on Tocolytics/Transfer Mother to Appropriate Level of Care if PossibleSee Annotation #37, "Stabilize on Tocolytics/Transfer Mother to Appropriate Level of Care if Possible," for a discussion about tocolytics.
42. Antenatal Corticosteroids 23-34 WeeksPlease refer to annotation #47, "Possibly Initiate Tocolytics, Antenatal Corticosteroids and Antibiotic Group B Streptococcus (GBS) Prophylaxis," for dosing of betamethasone and other corticosteroids.
47. Possibly Initiate Tocolytics, Antenatal Corticosteroids and Antibiotic Group B Streptococcus (GBS) ProphylaxisAgents to be considered for tocolytic therapy include terbutaline sulfate (including pump), indomethacin and nifedipine. In February 1997, the FDA alerted practitioners to use caution in the continuous subcutaneous administration of terbutaline sulfate.
Other considerations for initial management of preterm labor include the following:
• Initiate antenatal corticosteroids if 23-34 weeks gestation. Please refer below to "Pharmacologic Management of Preterm Labor" for more information on administration of betamethasone and other corticosteroids.
• Administer IV antibiotic effective against group B streptococcus (GBS) until GBS results are back or if patient is known to be positive for GBS (Thorp, 2002 [M]).
• Activity limitation as indicated.
• Order additional laboratory analysis pertinent to tocolytic being used.
Pharmacologic Management of Preterm LaborA. Tocolysis and betamethasone
Management of preterm labor should include parenteral tocolysis for 48 hours with administration of two doses of betamethasone.
The usual dosage regimen is betamethasone 12 mg IM STAT, then repeat in 24 hours.
An alternative medication is dexamethasone for a total of 24 mg (usual dosing regimen is 6 mg IM every 12 hours times four doses).
Treatment should be initiated in women with any symptoms or signs that might herald the onset of preterm delivery or a potential need for elective birth, rather than waiting until the diagnosis is in no doubt. While a single complete course of antenatal steroids provides significant multiple benefits to the preterm neonate, multiple courses should not be used. Please refer to the NIH Consensus Statement (Guinn, 2001 [A]; National Institutes of Health, 2000 [A]; Thorp, 2001 [A]).
Treatment should not be withheld because delivery appears to be imminent.
Antenatal corticosteroid therapy for fetal lung maturation reduces mortality, respiratory distress syndrome and intraventricular hemorrhage in preterm infants. These benefits extend to a broad range
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
19
of gestational ages and are not limited by gender or race (Crowley, 2002 [M]). New data indicate that the benefits of postnatal surfactant are enhanced by antenatal corticosteroid administration. No adverse consequences to a policy of administration of antenatal steroids to women in preterm labor have been identified (American College of Clinical Pharmacy, 2000 [R]; American College of Obestricians and Gynecologists, The, 2002a [R]).
The beneficial effects of corticosteroids are greatest more than 24 hours after beginning treatment. However, treatment less than 24 hours in duration may improve outcome. Every effort should be made to treat women before spontaneous or elective preterm delivery.
Aggressive Management with TocolysisTocolysis should be continued if necessary until fetal lung maturity is documented or maternal or fetal complications arise for which preterm delivery is indicated.
The etiology of preterm labor remains obscure. Consequently, patients who continue to have regular uterine activity and/or gradual cervical changes on parenteral tocolysis must be managed with clinical judgment, balancing the risks to the mother of ongoing tocolysis against the risks of preterm birth for the neonate.
For additional information regarding tocolytic therapy, please refer to the following: (American College of Obstetricians and Gynecologists, The, 1989 [R]; National Institutes of Health Consensus Development Conference Statement, 1995 [R]; Ogburn, 1990 [R]; Sanchez-Ramos, 1999 [M]).
Terbutaline PumpSeveral well-designed studies have concluded that terbutaline administered by infusion pump may be a safe and effective treatment option for the prolongation of pregnancy. However, there continues to be debate in the medical literature concerning the safety and efficacy of the pump (Allbert, 1994 [C]; Elliott, 1997 [D]; Perry, 1995 [D]).
Another study (Elliott, 2004 [B]), concludes that continuous subcutaneous terbutaline infusion was associ-ated with an exremely low incidence of serious events.
B. Administer antibiotics for group B streptococcus (GBS) prophylaxis until GBS results are back. Please refer to the GBS prophylaxis guidelines at your institution (Hager, 2000 [R]).
The Agency for HealthCare Research and Quality reviewed literature on the use of antibiotics in preterm labor (Agency for HealthCare Research and Quality, 2000 [M]).
(Centers for Disease Control and Prevention, 2002 [R])
49. Vaginal Pool + Amnio at 32+ Weeks for Fetal Lung Maturity (FLM)Phosphatidyl glycerol (PG) is a reliable indicator of FLM if present in vaginal pool specimens. L/S ratio is unreliable if blood and/or meconium are present in the fluid. Certain assays of PG may be influenced by the presence of heavy growth of gardnerella vaginalis. Please consult with your local hospital clinical laboratory (Beazley, 1996 [R]).
Maternal chorioamnionitis and hospital length of stay were lessened with induction of labor in preterm premature rupture of membranes (pPROM) with mature fetal lung maturity studies after 32 weeks, with no difference in neonatal outcomes compared with expectant management (Mercer, 1993 [R]).
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
20
51. Management of Preterm Labor with BleedingIn the presence of preterm labor with bleeding, IV access is essential.
• The patient should be on strict bedrest.
• Blood should be typed and crossmatched.
• Complete blood counts (CBCs) with platelets, prothrombin time (PT), partial thromboplastin time (PTT) and fibrinogen.
• Continue fetal monitoring while bleeding.
54. Deliver for Fetal Distress/Chorioamnionitis/Active Labor/34 Weeks PROM/Other Obstetrical IndicatorsUnder these conditions, we recommend delivery (Hauth, 2006 [M]).
A "break point" in neonatal morbidity was observed at 34 weeks gestation, which supports induction of labor at this gestional age (Neerhof, 1999 [B].
Vaginal Birth After Caesarean (VBAC) Algorithm Annotations
57. Special Considerations of Labor Management• Availability of a team capable of performing a Caesarean delivery within a short time (American College
of Obstetricians and Gynecologists, The Practice Bulletin, 2004 [R]).
• Review the prior operative report(s) to ensure that the uterine incision did not involve the contractile portion of the uterus such as a classical incision. A VBAC after a Caesarean with classical incision carries a tenfold higher risk of uterine rupture compared to a low transverse uterine incision.
• Intermittent auscultation or continuous electronic fetal heart rate monitoring should be done. See Intra-partum Fetal Heart Rate (FHR) Management algorithm and annotations.
• Augmentation or induction of labor with oxytocin increases the risk of uterine rupture (Blanchette, 2001 [C]) though the risk is still low (1%-2.4%). Oxytocin and prostaglandin were not individually associ-ated with uterine rupture except when sequential prostaglandin-oxytocin was used (Macones, 2005 [R]). A meta-analysis (Dodd, 2006 [R]) found sufficient evidence to help in choosing planned induction in VBAC versus elective repeat Caesarean delivery.
• The ACOG Committee on Obstetric Practice recommends that misoprostol not be used for induction of labor in women with prior Caesareans or major uterine surgery (American College of Obstetricians and Gynecologists, The, 2006 [R]).
• Use of the Foley bulb catheter has a uterine rupture rate close to that of women laboring spontaneously and has a VBAC success rate similar to that of women who have induced labor (Ravasia, 2000 [B]). The intracervical catheter ripening method does not stimulate uterine contractions, which is an advantage for women with previous Caesareans (Bujold, 2004 [B]). The Society of Obstetricians and Gynecologists of Canada has endorsed the use of the Foley bulb catheter for cervical ripening for women with a low transverse uterine scar. ACOG has no statement either endorsing or discouraging mechanical dilators for cervical ripening in women attempting VBAC (SOGC Clinical Practice Guidelines, 2005 [R]).
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
21
60. Complicated Labor ManagementThe same considerations for intervention in labor apply to VBACs as for other attempted deliveries.
Complicated labor can be manifested in several categories:
• Failure to progress – the same considerations for intervention – including amniotomy, oxytocin, epidural anesthesia/analgesia – apply to VBACs. If indication for primary Caesarean was dystocia, percentage successful VBACs was 77%. Women who required oxytocin for induction had 58% successful vaginal delivery versus 88% who required oxytocin for augmentation (Sakala, 1990 [C]; Silver, 1987 [D]; Stovall, 1987 [D]).
• Fetal distress – see Intrapartum Fetal Heart Rate (FHR) Management algorithm and annotations.
• Maternal complications – pre-eclampsia and exacerbation of pre-existing maternal illness are managed similarly in complicated VBAC versus a complicated vaginal labor patient.
• Uterine rupture – the scarred uterus has an increased potential to rupture. Uterine rupture occurs in between 1/100 and 1/11,000 deliveries, depending on whose data one uses and the clinical presenta-tion. The type of scar makes a difference in frequency of rupture and severity of symptoms, also (LST 0.2-0.8 Classical 4.3-8.8, T4.3-8.8, Low Vertical 0.5-6.5) (Pridjian, 1992 [R]).
Rupture through a low segment transverse scar is much more likely to go undetected or produce maternal hypovolemia or gradual fetal distress. Complete rupture with expulsion of fetus or placenta is a true obstetric emergency and can lead to maternal or hypovolemic complication, even death, as well as fetal hypoxia and death.
Conditions that increase the risk for uterine rupture:
• Previous uterine injury, Caesarean delivery, myomectomy, etc.
• Intrapartum – hyperstimulation, difficult forceps, internal podalic versions, fundal pressure, etc.
• Uterine defects not related to trauma, e.g., congenital defect, invasive mole
• Multiple previous Caesarean deliveries
Signs and symptoms of uterine rupture include:
• Fetal distress – 50%-70% of detected ruptures present with abnormal FH tracings (e.g., variable decelerations that evolve into late decelerations)
• Uterine pain, especially pain over previous incision that continues between contractions
• Hemorrhage – intra-abdominal, vaginal or urinary
• Palpation of fetal parts
• Loss of contractions
• Recession of presenting part
• Fetal death
Uterine scar disruptions can be classified into three types:
• Scar dehiscence – Opening of previous scar, with intact overlying peritoneum (uterine serosa), no expulsion of uterine contents
• Incomplete rupture – Opening of previous scar, but not overlying peritoneum, extraperitoneal extru-sion of intrauterine contents
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
22
• Complete rupture – Opening of previous scar and overlying peritoneum with extrusion of intrauterine contents into peritoneal cavity
(American College of Obstetrics and Gynecologists, 2006 [R]; Pridjian, 1992 [R])
Management of Labor Dystocia Algorithm Annotations
63. Labor Dystocia DiagnosisLabor abnormalities are classified as either protraction disorders (slower than normal progress) or arrest disorders (complete cessation of progress). Labor dystocia can only be defined when labor is in the active phase. Management of labor dystocia is especially important in the nulliparous woman to prevent unneeded Caesarean sections (Gifford, 2000 [D]).
Friedman provided the definition for "normal labor" in the 1950s. Further observation has shown that the definition of "normal labor" is broader than Friedman's definition. This has lead to more flexibility in the management of abnormal labor. Management strategies assume that mother and baby are doing well (including reassuring fetal monitoring).
65. Less than 1 cm Dilation for Two Consecutive Hours? Labor progress is measured by checking for cervical change using a digital cervical exam. Cervical exams should indicate at least one centimeter dilation per hour during the active phase. Frequent cervical checks afford the best opportunity to assess the progress of labor and to diagnose labor with abnormal progress.
At least one clinical trial testing the effectiveness of active management of labor in reducing Caesarean deliveries used hourly cervical exams; others studies have used every-two-hour exams. The "two-hour" rule for determining dilatation has been challenged. However, there is not enough supporting evidence to change our recommendation of "one-hour" cervical exams (American College of Obstetricians and Gynecologists, The Practice Bulletin, 2003a [R]; Frigoletto, 1995 [A]; Lopez-Zeno, 1992 [A]; Zhang, 2002 [C]).
66. Management of Protracted LaborProtracted labor is defined as labor which progresses more slowly than usual. "Active" management of labor as defined by O'Driscoll, et al does not reduce the rate of Caesarean delivery but may decrease the length of labor and increase patient satisfaction in nulliparas [Conclusion Grade II: See Conclusion Grading Worksheet B – Annotation #66 (Management of Protracted Labor)] (DeMott, 1992 [C]; Glantz, 1997 [M]; Harman, 1999 [R]; MN Clinical Comparison and Assessment Project, 1991 [R]; O'Driscoll, 1984 [C]).
Management of protraction disorders includes (Frigoletto, 1995 [A]; Lopez-Zeno, 1992 [A]; Sadler, 2000 [A]:
• Evaluation of the potential causes:
- Power: hypocontractile uterine activity is the most common cause of first stage of labor abnor-malities. Adequate contractions are defined as a minimum of 200 Montevideo units in 10 minutes.
- Passenger: check for malposition, malpresentation, macrosomia.
- Passageway: is pelvis adequate? Is there cephalopelvic disproportion?
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
23
Consider:
• IV fluids (IV fluids 150 cc/hr may decrease the need for oxytocin augmentation) (Garite, 2000 [A].
• Artificial rupture of membranes if membranes are intact and there are no contraindications. (See Annotation #11, "Intrapartum Care.")
Amniotomy may be used to enhance progress in active labor (may decrease length of labor and decrease the need for oxytocin augmentation), but may increase the rate of maternal fever. First-stage amniotomy should be reserved for slowly progressing labors (Fraser, 2000 [M]).
• Discontinuing or reducing epidural anesthesia, as the use of epidurals has been shown to increase the length of labor. However, there is no increased rate of Caesarean birth for dystocia when epidural anesthesia is in use (King, 1997 [R]; Rogers, 1999 [C]).
• Oxytocin augmentation. The use of low-dose or high-dose dosing regimens has been shown to shorten labor by hours (Hinshaw, 2008 [A].
Contraindications to oxytocin augmentation include:
• unknown presentation or floating/unstable,
• patient refusal, and
• inability to monitor contractions adequately.
• Obtain an obstetrical/surgical consult if necessary. Caesarean delivery is performed when there is an arrest of labor: patient has not made progress for two to four hours after strength of contractions deemed adequate (regardless of oxytocin dosage or duration of oxytocin).
Extending time of observation to four hours before operative treatment has been shown to decrease the Caesarean delivery rate for arrested labor (Rouse, 2001 [A]). Although studies of single aspects of "active" management of labor have not demonstrated a decrease in the rate of Caesarean delivery, an analysis of the literature suggests that some combination of active management techniques will lead to an overall decrease in the rate of Caesarean delivery (Turner, 1988 [C]).
71. Fetal Head Descent Greater than 1 cm/Hour? When the patient has reached Stage II labor, a reassessment at least every 30 minutes for two consecutive hours is done to assess descent of the fetus and rotation of the fetus. If the patient is making appropriate progress, the caregiver can anticipate vaginal delivery. Fetal descent should be greater than 1 cm per hour.
If labor is not progressing, consider an internal monitor to measure strength of uterine contractions. After two hours of internal monitoring there should be enough evidence to determine if patient is making progress (Harbert, 1992 [R]).
Relative contraindications to direct, invasive monitoring include chorioamnionitis, active maternal genital herpes infection and HIV infection, certain fetal presentations and conditions that preclude vaginal examinations such as placenta previa or undiagnosed vaginal bleeding (Association of Women's Health Obstetrics and Neonatal Nurses, 2003 [R]).
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
24
73. Management of Protracted Labor If the patient in Stage II labor is not making progress, management of protraction disorders will include:
• Evaluation of maternal and fetal position. Consider having the patient move into different posi-tions.
• Oxytocin augmentation.
• Allowing fetus to "labor down." Do not start active pushing as soon as patient is fully dilated. Allow contractions to move the baby down (Fraser, 2000a [A]).
• Decreasing or stopping epidural anesthesia. Epidural anesthesia is associated with a prolongation of the second stage of labor and an increase in oxytocin use and assisted vaginal delivery (Shields, 2007 [R]).
• Evaluation of fluid balance may be beneficial for affecting labor progress (American College of Obstetricians and Gynecologists, The, 2003 [R]).
• Consideration of assisted delivery.
• OB/surgical consult if necessary.
(Minnesota Clinical Comparison and Assessment Project, 1991 [R]; Saunders, 1992 [B])
74. Is the Head Descending?Prolongation of the second stage of labor beyond an arbitrary time limit is no longer an indication for assisted vaginal or Caesarean delivery. As long as progress is being made and fetal monitoring is reassuring, the patient can continue pushing (Cheng, 2004 [A]; Myles, 2003 [B]).
75. Assisted Vaginal Delivery Indicated? If there is no descent for two hours despite optimizing labor, an assisted delivery or surgical consult is suggested. Vacuum extraction or mid/low forceps delivery contraindications include:
• vertex is too high,
• provider is inexperienced,
• fetal distress with inability to do timely operative vaginal delivery, and
• patient refusal.
Note: When using vacuum extraction or forcep application with a suspected macrosomic infant, be aware of the risk of shoulder dystocia.
(O'Driscoll, 1984 [C]; Rouse, 2001 [D]; Shields, 2007 [R])
Intrapartum Fetal Heart Rate (FHR) Monitoring Algorithm Annotations
78. Continuous EFM-ext or EFM-int (if needed) Electronic fetal monitoring (EFM) is indicated in all high-risk situations and in low-risk situations when the auscultatory pattern is unclear or when 1:1 nursing staff is not available. Internal EFM may allow easier patient positioning and promote patient activity by being less confining than external EFM. Low-risk patients should be encouraged to be as active and mobile as possible.
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
25
80. FHR Pattern Is Predictive of Normal Acid-Base Status? All obstetrical nurses, nurse midwives and physicians must achieve competence and confidence in fetal heart rate monitoring and FHR pattern analysis. Based on careful review of the available options, a three-tier system for the categorization of FHR patterns is recommended. Fetal heart rate tracing patterns can provide information on the current acid-base status of the fetus but cannot predict the development of cerebral palsy. Categorization of the FHR tracing evaluates the fetus at that point in time; tracing patterns can and will change (Macones, 2008 [R]).
Category of
FHR Pattern
Interpretation
Baseline and
Variability
Accelerations
(15 x 15)
Decelerations Interventions
Category I:
strongly
predictive of
normal fetal acid-
base status
• BL 110-160
• Moderate
variability
• Present or
absent
+/- Early decels
• No variable or
late decelerations
No specific
interventions
required, ongoing
assessment and
evaluation.
Category II:
Indeterminate.
Not predictive of
abnormal fetal
acid-base status
• BL < 110
without absent
variability
• BL > 160
• Marked
variability
• Absent
variability
without
decelerations
• Absence of
accelerations
after fetal
stimulation
• Prolonged
decelerations
(> 2 minutes but
< 10 minutes)
• Recurrent late
decels with
moderate
variability
• Recurrent variable
decels with
minimal or
moderate
variability
Requires evaluation
and continued
surveillance. Review
and take into account
associated clinical
circumstances.
Category III:
Predictive of
abnormal fetal
acid-base status at
the time of
observation
• Absent
variability and
any of the
following:
• Recurrent late
decels
• Recurrent
variable decels,
• BL < 110
• Sinusoidal
pattern
Prompt evaluation
and management
indicated. May
include:
• Maternal position
change
• Maternal oxygen
• Discontinuation of
labor stimulus
• Treatment of
possible underlying
condition
• Expedited delivery
Developed by the guideline committee.
Source: American College of Obstetricians and Gynecologists, The, 2005 and Macones, 2008
Definitions:
Late decelerations
• Deceleration is delayed in timing, onset-to-nadir if the deceleration is 30 seconds or greater, and there is a gradual decrease and return to baseline.
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
26
Early decelerations
• Onset, nadir and recovery mirror the beginning, peak and ending of the contraction.
Variable decelerations
• Abrupt decrease in the FHR with onset to nadir of deceleration reached in less than 30 seconds, decrease in FHR is 15 seconds or greater and less than two minutes in duration.
Variability
• Fluctuations in the FHR baseline over a 10-minute window, accelerations and decelerations are not included in the range.
• Absent - amplitude range is undetectable.
• Minimal - amplitude range is between 2 beats per minutes (bpm) and 5 bpm.
• Moderate - amplitude range is between 6 bpm and 25 bpm.
• Marked - amplitude range is greater than 25 bpm.
Recurrent
• Decelerations that occur with 50% or greater of uterine contractions in any 20-minute window.
Sinusoidal pattern
• Cyclic, smooth, sine wavelike undulating pattern in the FHR baseline frequency cycle of 3-5 per minute that persists for 20 minutes or longer.
(American College of Obstetricians and Gynecologists, The, 2005 [R]; Macones, 2008 [R])
82. Assessment and Remedial Techniques A persistent Category II or Category III FHR tracing requires evaluation of the possible causes. Initial evaluation and treatment may include:
• discontinuation of any labor stimulating agent;
• cervical examination to assess for umbilical cord prolapse or rapid cervical dilation or descent of the fetal head;
• changing maternal position to the left or right lateral recumbent position, reducing compression of the vena cava and improving uteroplacental blood flow;
• monitoring maternal blood pressure level for evidence of hypotension, especially in those with regional anesthesia (if present, treatment with ephedrine or phenylephrine may be warranted);
• assessment of patient for uterine hyperstimulation by evaluating uterine contraction frequency and duration; and
• amnioinfusion – indications for therapeutic amnioinfusion include repetitive severe variable decel-erations and prolonged decelerations (Fraser, 2005 [A]; Miyazaki, 1985 [A]; Rinehart, 2000 [A]). Amnioinfusion for thick meconium is no longer recommended.
(American College of Obstetricians and Gynecologists, The Practice Bulletin, 2005 [R])
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
27
86. Further FHR Assessment Predictive of Normal Acid-Base Status? Obtain obstetrical or surgical consultation or referral where needed to plan for operative delivery if the FHR pattern is Category III. Category III tracings are predictive of fetal academia. Consider contacting a neonatology team to plan for possible neonatal intervention.
Scalp stimulation or vibroacoustic testing may be used for further fetal assessment. A 15-beat-per-minute rise in FHR lasting 15 seconds from the beginning to the end of the acceleration in response to scalp stimu-lation or to vibration or sound is predictive of normal fetal acid-base status. If the scalp stimulation test or vibroacoustic test response is abnormal, immediate delivery is indicated.
Other tests to assess fetal acid-base status may be helpful if available. This includes fetal scalp sampling for PH. A scalp pH greater than 7.19 is a positive result (Skupski, 2002 [M]; Smith, 1986 [D]).
However, proper FHR pattern interpretation and the response to scalp stimulation or vibroacoustic stimula-tion can allow the clinician to detect tracings predictive of abnormal feta acid-base status.
Knowledge of the fetal oxygen saturation is not associated with a reduction in the rate of Caesarean delivery or with improvement in the condition of the newborn (Bloom, 2006 [A]).
87. Emergent Delivery Tracings predictive of abnormal fetal acid-base status (Category III) indicate the need for emergent delivery. Delivery should be affected by appropriate means, depending on the clinical situation. This may include vacuum extraction, forceps or Caesarean delivery, depending upon fetal presentation and the expertise of the attending physician(s).
Caesarean delivery should be performed if vacuum extraction or forceps are inappropriate for use.
If a Caesarean delivery is performed, the suitability of a VBAC in a subsequent pregnancy should be discussed with the patient.
The following are indications for Caesarean birth based on abnormal FHR monitoring, according to the Minnesota Clinical Comparison and Assessment Project:
• Late decelerations that comprise the majority of contractions over a minimum 20-minute period in the absence of adequate beat-to-beat variability and that do not respond to remedial techniques.
• Severe variable decelerations that comprise the majority of contractions over 20-60 minutes and that do not respond to remedial techniques.
• Severe persistent non-remediable bradycardia.
• Scalp pH less than 7.2 or negative FHR acceleration test (confirmation in 15-20 minutes recom-mended).
• There may be other combinations or non-remediable patterns that may not meet severity criteria listed above that may be indications for preparation for Caesarean birth. A scalp pH or FHR acceleration test (scalp or acoustic) may help clarify the issue. Consultation or second opinion is suggested.
• In the second stage of labor, depending on the judgment and skill of the physician, operative vaginal delivery may be the least hazardous for the mother and child.
If one-minute APGAR is less than three, or five-minute APGAR is less than six, cord pH or gases are recommended. Cord pH is a better indicator than APGAR for fetal compromise. A segment of umbilical cord is isolated with clamps and may be stored up to 60 minutes after delivery with reliable umbilical artery pH determination. The segment does not need to be heparinized or placed on ice (Duerbeck, 1992 [D]; Johnson, 1993 [D]).
Management of Labor Algorithm Annotations Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
28
Appendix A – Patient Education Handout
Management of Labor Third Edition/May 2009
ACTIVE MANAGEMENT OF LABORIs active management of labor for you?
This is for you if you are going to be giving birth for the first time, you are healthy and are within three weeks of your due date, and the baby is in the usual head-down position.
This is not for you if you have delivered a baby before, or if you are having your labor induced (started) in the hospital, or if you are expecting more than one baby.
Why is active management of labor used?
Active management of labor is a method of intervention that prevents labor from lasting too long. Prolonged labor increases a woman's risk of exhaustion, infection, hemorrhage after delivery and need for Caesarean delivery.
Recent studies in both the United States and abroad have demonstrated clear benefits of this intervention. Active management of labor does not cause any increased risks to the baby.
How is active management of labor used?
It begins when you are admitted to the hospital in labor, and you are having regular contractions at least every five to seven minutes. When your cervix is effaced (thinned out) and dilated to 3 centimeters or more, your care provider will check if your membranes have ruptured (water has broken). If not, the membranes will be opened unless the baby's head is too high. This procedure is known as an "amniotomy." The amniotic fluid will then start to leak out. This procedure may be enough to keep your labor progressing and prevent it from lasting a long time.
During your labor, you will need to have a vaginal exam every two hours or so to check your progress. If your cervix continues to dilate at least one centimeter or more per hour, your labor is making normal progress.
If your labor progress stalls and your cervix changes too slowly (less than 1 centimeter in two hours), your labor will be augmented with a medication, oxytocin.
Oxytocin (Pitocin) Augmentation
Pitocin is a synthetic hormone that helps to increase the strength of the contractions and make them more effective. It is given through an intravenous (IV) drip and the amount is carefully monitored.
A fetal monitor will be used to follow the baby's heartbeat and record the contractions.
You will still be able to move around and change positions for your own comfort. You can certainly also receive pain relief as needed.
Failure to Progress
If following this labor management plan does not progress to vaginal delivery, you will need a Caesarean delivery. Active management does not increase your chances of failure to progress; however, it can shorten the time between the beginning of your labor and when the decision is made for a Caesarean delivery. This can help in your recovery from surgery.
Institute for Clinical Systems Improvement
www.icsi.org
29
The third stage of labor (delivery of placenta)
Following delivery of the baby, oxytocin can be given to help your uterus contract to deliver the placenta and control bleeding. This can be given through your intravenous drip (if you have one) or as a shot. Studies have shown that this management reduces the rate of heavy bleeding after delivery, anemia (low iron in the blood) and the need for blood transfusion.
How do women like active management of labor?
Many women like having an idea of knowing how long their labor will last and knowing that it will not last too long. After delivery, they have more energy to enjoy their baby and to get breast-feeding off to a good start.
This information is meant to enhance but not replace what you learn in childbirth education classes. Child-birth education classes are highly recommended.
Please discuss further questions with your pregnancy care provider during your prenatal visits.
Management of Labor Appendix A – Patient Education Handout Third Edition/May 2009
30Copyright © 2009 by Institute for Clinical Systems Improvement
Released in May 2009 for Third Edition. The next scheduled revision will occur within 24 months.
Contact ICSI at: 8009 34th Avenue South, Suite 1200; Bloomington, MN 55425; (952) 814-7060; (952) 858-9675 (fax)
Online at http://www.ICSI.org
I ICSI NSTITUTE FOR C LINICAL S YSTEMS I MPROVEMENT
Document Drafted Jul – Sep 2005
First Edition Nov 2005
Second Edition Apr 2007
Third Edition Begins Jun 2009
Supporting Evidence:
Management of Labor
Original Work Group MembersThe Management of Labor guideline is the result of merging the Preterm Birth Prevention (Preterm), Intrapartum Fetal Heart Rate Monitoring (IFHRM), The Prevention, Diagnosis and Treatment of Failure to Progress in Obstetrical Labor (FTP), and Vaginal Birth after Caesarean (VBAC) guidelines.
Health EducationDianne Eggen, RN, MPH – PretermHealthPartnersFamily PracticeGreg Angstman, MD – IFHRMMayo ClinicAndy Bock, MD – FTPMayo ClinicDonald Lum, MD – VBACRiverValleyClinicofNorthfieldCarol Stark, MDMinnHealth Family PhysiciansNurse MidwifeSandy Lindell – IFHRMTwin City OB/Gyn, Ltd.Debra Monson, CNM – VBACTwin City OB/Gyn, Ltd.Mary Jo Rourke, CNM – FTPGroup Health, Inc.Nurse PractitionerJulie Rice, RN, NP – PretermHealthSystem MinnesotaOB/GYNDale Akkerman, MD – VBACPark Nicollet Medical Center
Work Group Leaders John Farr, MD – FTPOB/Gyn Twin City OB/Gyn, Ltd.John Hering, MD – VBACObstetricianGroup Health, Inc.Peter Mark, MD – PretermOB/GynHealthPartnersLeslie Pratt, MD – PretermOB/GynHealthSystem MinnesotaDeborah Thorp, MD – IFHRMOB/GynPark Nicollet Medical CenterBusiness Health Care Action GroupKathy Halvorsen, RN – VBACHoneywell Inc.Terry Kent, RN, MS – PretermHoneywell, Inc.Marcia McCarty – FTPTarget StoresAnne Widtfeldt – IFHRMHoneywell, Inc.
John Hachiya, MD – FTPPark Nicollet Medical CenterJaved Malik, MD – FTPGroup Health, Inc.Paul Ogburn, MD – VBAC, PretermMayo ClinicCharles Stegeman, MD – IFHRMGroup Health, Inc.John Underwood, MD – IFHRMCoon Rapids Medical CenterMeasurement AdvisorRick Carlson – FTP, IFHRM, VBACGroup Health, Inc.Leif Solberg, MD – PretermGroup Health FoundationFacilitatorsKatie Conlin, RN, MPH – VBACGroup Health, Inc.Stacie Emberley, RN – VBACICSIBrenda Gorder, RN – FTPGroup Health, Inc.Jackie Rikhus, RN – PretermICSI
Institute for Clinical Systems Improvement
www.icsi.org
31
Individual research reports are assigned a letter indicating the class of report based on design type: A, B, C, D, M, R, X.
A full explanation of these designators is found in the Foreword of the guideline.
II. CONCLUSION GRADES
Key conclusions (as determined by the work group) are supported by a conclusion grading worksheet that summarizes the important studies pertaining to the conclusion. Individual studies are classed according to the system defined in the Foreword and are assigned a designator of +, -, or ø to reflect the study quality. Conclusion grades are determined by the work group based on the following definitions:
Grade I: The evidence consists of results from studies of strong design for answering the question addressed. The results are both clinically important and consistent with minor exceptions at most. The results are free of any significant doubts about generalizability, bias, and flaws in research design. Studies with negative results have sufficiently large samples to have adequate statistical power.
Grade II: The evidence consists of results from studies of strong design for answering the question addressed, but there is some uncertainty attached to the conclusion because of inconsistencies among the results from the studies or because of minor doubts about generalizability, bias, research design flaws, or adequacy of sample size. Alternatively, the evidence consists solely of results from weaker designs for the question addressed, but the results have been confirmed in separate studies and are consistent with minor exceptions at most.
Grade III: The evidence consists of results from studies of strong design for answering the question addressed, but there is substantial uncertainty attached to the conclusion because of inconsistencies among the results from different studies or because of serious doubts about generalizability, bias, research design flaws, or adequacy of sample size. Alternatively, the evidence consists solely of results from a limited number of studies of weak design for answering the question addressed.
Grade Not Assignable: There is no evidence available that directly supports or refutes the conclu-sion.
The symbols +, –, ø, and N/A found on the conclusion grading worksheets are used to designate the quality of the primary research reports and systematic reviews:
+ indicates that the report or review has clearly addressed issues of inclusion/exclusion, bias, generaliz-ability, and data collection and analysis;
– indicates that these issues have not been adequately addressed;
ø indicates that the report or review is neither exceptionally strong or exceptionally weak;
N/A indicates that the report is not a primary reference or a systematic review and therefore the quality has not been assessed.
Brief Description of Evidence Grading System
Management of Labor Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
32
References
Agency for HealthCare Research and Quality. Management of preterm labor. Evidence Report/Tech-nology Assessment: Number 18. Publication (No. 01-E021), October 2000. (Class M)
Alfirevic Z, Devane D, Gyte GML. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour (review). The Cochrane Library 2009, Issue 1. (Class M)
Allbert JR, Johnson C, Roberts WE, et al. Tocolysis for recurrent preterm labor using a continuous subcutaneous infusion pump. J Reprod Med 1994;39:614-18. (Class C)
American College of Clinical Pharmacy. Preterm Labor. Pharmacotherapy self-assessment program. 3rd ed. Module 11: Women's Health, Kansas City: American College of Clinical Pharmacy, 2000. (Class R)
American College of Obstetricians and Gynecologists, The. Induction of labor for vaginal birth after Cesarean delivery. Obstet Gynecol 2006;108:465-67. (Class R)
American College of Obstetricians and Gynecologists, The. Preterm labor. American College of Obstetricians and Gynecologists, The Technical Bulletin; 1989;133:1-6. (Class R)
American College of Obstetricians and Gynecologists, The, and American Academy of Pediatrics. In Guidelines for Perinatal Care, 6th ed. Washington DC: American College of Obstetricians and Gyne-cologists, The and AAP. 2008;139-59. (Class R)
American College of Obstetricians and Gynecologists, The, Committee on Obstetric Practice. Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2002a;99:871-73. (Class R)
American College of Obstetricians and Gynecologists, The, Committee Opinion. Induction of labor for vaginal birth after Caesarean delivery. Obstet Gynecol 2002b;99:679-80. (Class R)
American College of Obstetricians and Gynecologists, The, Practice Bulletin. Dystocia and augmenta-tion of labor. Number 49, December 2003. (Class R)
American College of Obstetricians and Gynecologists, The, Practice Bulletin. Intrapartum fetal heart rate monitoring. 2005;106:1453-61. (Class R)
American College of Obstetricians and Gynecologists, The, Practice Bulletin. Vaginal birth after previous Caesarean delivery. 2004;104:203-12. (Class R)
Andrews WW, Goldenberg RL, Mercer B, et al. The preterm prediction study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am J Obstet Gynecol 2000;183:662-68. (Class C)
Anotayanonth S, Subhedar NV, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour (review). The Cochrane Library 2009, Issue 1. (Class M)
Association of Women's Health Obstetrics and Neonatal Nurses. In Fetal Heart Monitoring Principles and Practices. 3rd Ed. Dubuque: Kendall/Hunt Publishing Co., 2003. (Class R)
Bar J, Maayan-Metsger A, Hod M, et al. Effect of antibiotic therapy in preterm premature rupture of the membranes on neonatal mortality and morbidity. Am J Perinatology 2000;17:237-41. (Class C)
Beazley D, Lewis R. The evaluation of infection and pulmonary maturity in women with premature rupture of the membranes. Seminars in Perinatology 1996;20:409-17. (Class R)
Blanchette H, Blanchette M, McCabe J, Vincent S. Is vaginal birth after Caesarean safe? Experience at a community hospital. Obstet Gynecol 2001;184:1478-87. (Class C)
Management of Labor Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
33
Bloom SL, Spong CY, Thom E, et al. Fetal pulse oximetry and Caesarean delivery. N Engl J Med 2006;355:2195-202. (Class A)
Boylan P, Frankowski R, Rountree R, et al. Effect of active management of labor on the incidence of Caesarean delivery for dystocia in nulliparas. Am J Perinatol 1991;8:373-79. (Class C)
Brisson-Carroll G, Fraser W, Breart G, et al. The effect of routine early amniotomy on spontaneous labor: a meta-analysis. Obstet Gynecol 1996;87:891-96. (Class M)
Bujold E, Blackwell SC, Gauthier RJ. Cervical ripening with transcervical foley catheter and the risk of uterine rupture. Obstet Gynecol 2004;103:18-23. (Class B)
Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534-40. (Class A)
Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. MMWR 2002;51. No. RR-11. (Class R)
Cheng YW, Hopkins LM, Caughey AB. How long is too long: does a prolonged second stage of labor in nulliparous women affect maternal and neonatal outcomes? Am J Obstet Gynecol 2004;191:933-38. (Class B)
Cheyne H, Dunlop A, Shields N, Mathers AM. A randomised controlled trial of admission electronic fetal monitoring in normal labour. Midwifery 2003;19:221-29. (Class A)
Clark A, Carr D, Loyd G, et al. The influence of epidural analgesia on Caesarean delivery rates: a randomized, prospective clinical trial. Am J Obstet Gynecol 1998;179:1527-33. (Class A)
Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990;163:767-72. (Class A)
Crowley P. Prophylactic corticosteroids for preterm birth. The Cochrane Library 2002. (Class M)
Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour (review). The Cochrane Library 2009, Issue 1. (Class M)
da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24. (Class A)
DeMott RK, Sandmire HF. The Green Bay Caesarean delivery study. II. The physician factor as a determinant of Caesarean birth rates for failed labor. Am J Obstet Gynecol 1992;166:1799-1810. (Class C)
Dodd JM, Crowther CA. Elective repeat Caesarean section versus induction of labour for women with a previous Caesarean birth (review). The Cochrane Library 2009, Issue 1. (Class M)
Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (review). The Cochrane Library 2009, Issue 1. (Class M)
Doyle NM, Gardner MO, Wells L, et al. Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis. J Perinatol 2005;25:336-40. (Class B)
Duerbeck NB, Chaffin DG, Seeds JW. A practical approach to umbilical artery pH and blood gas determinations. Obstet Gynecol 1992;79:959-62. (Class D)
East CE, Dunster KR, Colditz PB, et al. Fetal oxygen saturation monitoring in labour: an analysis of 118 cases. Aust NZ J Obstet Gynaecol 1997;37:397-401. (Class D)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
34
Edwards RK, Locksmith GJ, Duff P. Expanded-spectrum antibiotics with preterm premature rupture of membranes. Obstet Gynecol 2000;96:60-64. (Class C)
Elbourne DR, Prendiville WJ, Carroli G, et al. Prophylactic use of oxytocin in the third stage of labour. Cochrane Database Syst Rev 2001;(4):CD001808. (Class M)
Elliott JP, Flynn MJ, Kaemmerer EL,et al. Terbutaline pump tocolysis in high-order multiple gestation. J Reprod Med 1997;42:687-94. (Class D)
Elliott JP, Istwan NB, Rhea D, Stanziano G. The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy. Am J Obstet Gynecol 2004;191:1277-82. (Class B)
Flamm BL, Lim OW, Jonec C, et al. Vaginal birth after Caesarean section: results of a multicenter study. Am J Obstet Gynecol 1988;158:1079-84. (Class D)
Fraser WD, Hofmeyr J, Lode R, et al. Amnioinfusion for the prevention of the meconium aspiration syndrome. N Engl J Med 2005;353:909-17. (Class A)
Fraser WD, Marcoux S, Krauss I, et al. Multicenter, randomized, controlled trial of delayed pushing for nulliparous women in the second stage of labor with continuous epidural analgesia. Am J Obstet Gynecol 2000a;182:1165-72. (Class A)
Fraser WD, Marcoux S, Moutquin JM, et al. Effect of early amniotomy on the risk of dystocia in nullipa-rous women. N Engl J Med 1993;328:1145-49. (Class A)
Fraser WD, Turcot L, Krauss I, Brisson-Carrol G. Amniotomy for shortening spontaneous labour. In The Cochrane Library 4:2000b. Oxford: Update software. (Class M)
Freeman RK. Problems with intrapartum fetal heart rate monitoring interpretation and patient manage-ment. Obstet Gynecol 2002;100:813-26. (Class R)
Frigoletto FD Jr, Lieberman E, Lang JM, et al. A clinical trial of active management of labor. N Engl J Med 1995;333:745-50. (Class A)
Garite TJ, Dildy GA, McNamara H, et al. Transactions of the twentieth annual meeting of the society for maternal-fetal medicine–continued. A multicenter controlled trial of fetal pulse oximetry in the intra-partum management of nonreassuring fetal heart rate patterns. Am J Obstet Gynecol 2000;183:1049-58. (Class A)
Garite TJ, Porto M, Carlson NJ, et al. The influence of elective amniotomy on fetal heart rate patterns and the course of labor in term patients: a randomized study. Am J Obstet Gynecol 1993;168:1827-32. (Class A)
Garite TJ, Weeks J, Peters-Phair K, et al. A randomized controlled trial of the effect of increased intrave-nous hydration on the course of labor in nulliparous women. Am J Obstet Gynecol 2000;183:1544-48. (Class A)
Gifford DS, Morton SC, Fiske M, et al. Lack of progress in labor as a reason for Cesarean. Obstet Gynecol 2000;95:589-95. (Class D)
Glantz JC, McNanley TJ. Active management of labor: a meta-analysis of Caesarean delivery rates for dystocia in nulliparas. Obstet Gynecol Surv 1997;52:497-505. (Class M)
Goldenberg RL, Cliver SP, Bronstein J, et al. Bedrest in pregnancy. Obstet Gynecol 1994;84:131-36. (Class R)
Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006;108:986-89. (Class R)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
35
Guinn DA, Atkinson MW, Sullivan L, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA 2001;286:1581-87. (Class A)
Guinn DA, Goepfert AR, Owen J, et al. Management options in women with preterm uterine contrac-tions: a randomized clinical trial. Am J Obstet Gynecol 1997;177:814-18. (Class A)
Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94:869-77. (Class M)
Hager WD, Schuchat A, Gibbs R, et al. Prevention of perinatal group B streptococcal infection: current controversies. Obstet Gynecol 2000;96:141-45. (Class R)
Halpern SH, Leighton BL, Ohlsson A, et al. Effect of epidural vs parenteral opioid analgesia on the progress of labor. JAMA 1998;280:2105-10. (Class M)
Harbert GM Jr. Assessment of uterine contractility and activity. Clin Obstet Gynecol 1992;35:546-58. (Class R)
Harman JH, Kim A. Current trends in cervical ripening and labor induction. Am Fam Physician 1999;60:477-84. (Class R)
Hauth JC. Spontaneous preterm labor and premature rupture of membranes at late preterm gestations: to deliver or not to deliver. Semin Perinatol 2006;30:98-102. (Class M)
Haverkamp AD, Thompson HE, McFee JG, Cetrulo C. The evaluation of continuous fetal heart rate monitoring in high-risk pregnancy. Am J Obstet Gynecol 1976;125:310-21. (Class A)
Hinshaw K, Simpson S, Cummings S, et al. A randomised controlled trial of early versus delayed oxytocin augmentation to treat primary dysfunctional labour in nulliparous women. BJOG 2008;115:1289-96. (Class A)
Impey L, Reynolds M, MacQuillan K, et al. Admission cardiotocography: a randomised controlled trial. Lancet 2003;361:465-70. (Class A)
International Confederation of Midwives, International Federation of Gynaecologists and Obstetricians. Joint statement: management of the third stage of labour to prevent post-partum haemorrhage. J Midwifery Womens Health 2004;49:76-77. (Class R)
Kenyon S, Boulvain M. Antibiotics for preterm premature rupture of membranes (Cochrane Review). In The Cochrane Library, Issue 4, 2000. Oxford: Update Software. (Class M)
King J, Flenady V, Cole S, Thornton S. Cycle-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005:CD001992. (Class M)
King JF, Flenady VJ, Papatsonis DN, et al. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2003;CD002255. (Class M)
King T. Epidural anesthesia in labor: benefits versus risks. J Nurse Midwifery 1997;42:377-88. (Class R)
Kühnert M, Goebel-Seelbach B, Butterwegge M. Predictive agreement between the fetal arterial oxygen saturation and fetal scalp pH: results of the German multicenter study. Am J Obstet Gynecol 1998;178:330-35. (Class C)
Langer B, Boudier E, Haddad J, et al. Fetal pulse oximetry during labor of 62 patients. Fetal Diagn Ther 1996;11:37-45. (Class C)
Lavender T, Alfirevic Z, Walkinshaw S. Partogram action line study: a randomised trial. Br J Obstet Gynaecol 1998;105:976-80. (Class A)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
36
Lavender T, Wallymahmed AH, Walkinshaw SA. Managing labor using partograms with different action lines: a prospective study of women's views. Birth 1999;26:89-96. (Class A)
Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003;189:139-47. (Class M)
Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol 2005;106:173-79. (Class M)
López-Zeno JA, Peaceman AM, Adashek JA, Socol Ml. A controlled trial of a program for the active management of labor. N Engl J Med 1992;326:450-54. (Class A)
Macones GA, Hankins GDV, Spong Y, et al. The 2008 national institute of child health and human development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008;112:661-66. (Class R)
Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after Cesarean delivery: a multicenter study. Am J Obstet Gynecol 2005;193:1656-62. (Class C)
Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007;114:310-18. (Class A)
McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo-controlled trial. Br J Obstet Gynaecol 1997;104:1391-97. (Class A)
McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol 1995;173:157-67. (Class C)
McNiven P, Hodnett E, O'Brien-Pallas LL. Supporting women in labor: a work sampling study of the activities of labor and delivery nurses. Birth 1992;19:3-9. (Class D)
Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxypro-gesterone caproate. N Engl J Med 2003;348:2379-85. (Class A)
Menard MK, Liu Q, Holgren EA, Sappenfield WM. Neonatal mortality for very low birthweight deliv-eries in South Carolina by level of hospital perinatal service. Am J Obstet Gynecol 1998;179:374-81. (Class C)
Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. Am J Obstet Gynecol 1993;169:775-82. (Class A)
Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial. JAMA 1997;278:989-95. (Class A)
Minnesota Clinical Comparison and Assessment Project. Caesarean birth: practice guidelines and recommendations. Page 11, March 1991. (Class R)
Mittendorf R, Dambrosia J, Pryde PG, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186:1111-18. (Class R)
Miyazaki FS, Nevarez F. Saline amnioinfusion for relief of repetitive variable decelerations: a prospec-tive randomized study. Am J Obstet Gynecol 1985;153:301-06. (Class A)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
37
Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994;171:345-49. (Class A)
Myles TD, Santolaya J. Maternal and neonatal outcomes in patients with a prolonged second stage of labor. Obstet Gynecol 2003;102:52-58. (Class B)
Naiden J, Deshpande P. Using active management of labor and vaginal birth after previous Caesarean delivery to lower Caesarean delivery rates: a 10-year experience. Obstet Gynecol 2001;184:1535-43. (Class D)
National Institutes of Health Consensus Development Conference Statement. Antenatal corticoste-roids revisited: repeat courses. Antenatal Corticosteroids Revisited: Repeat Courses. NIH Consensus Statement Online 2000;27:1-10. (Class R)
National Institutes of Health Consensus Development Conference Statement. Effect of corticosteroids for fetal maturation on perinatal outcomes. Am J Obstet Gynecol 1995;173:246-52. (Class R)
Neerhof MG, Cravello C, Haney EI, Silver RK. Timing of labor induction after premature rupture of membranes between 32 and 36 weeks' gestation. Am J Obstet Gynecol 1999;180:349-52. (Class B)
O'Driscoll K, Foley M, MacDonald D. Active management of labor as an alternative to Cesarean section for dystocia. Obstet Gynecol 1984;63:485-90. (Class C)
Ogburn PL Jr. The treatment of preterm labor. Postgrad Obstet Gynecol 199010:1-6. (Class R)
Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of fish oil supplementation in high-risk pregnancies. Br J Obstet Gynaecol 2000;107:382-95. (Class A)
Papatsonis DNM, Van Geijn HP, Ader HJ, et al. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol 1997;90:230-34. (Class A)
Perry KG,Morrison JC, Rust OA, et al. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol 1995;173:1273-77. (Class D)
Phelan JP, Ahn MO, Diaz F, et al. Twice a Caesarean, always a Caesarean? Obstet Gynecol 1989;73:161-65. (Class C)
Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after Caesarean. Am J Obstet Gynecol 1987;157:1510-15. (Class C)
Pitt C, Sanchez-Ramos L, Kaunitz AM, Francisco G. Prophylactic amnioinfusion for intrapartum oligo-hydramnios: a meta-analysis of randomized controlled trials. Obstet Gynecol 2000;96:861-66. (Class M)
Pridjian G. Labor after prior Caesarean section. Clin Obstet Gynecol 1992;35:445-56. (Class R)
Radin TG, Harmon JS, Hanson DA. Nurses' care during labor: its effect on the Caesarean birth rate of healthy, nulliparous women. Birth 1993;20:14-21. (Class C)
Ravasia DJ, Wood SL, Pollard JK. Uterine rupture induced trial of labor among women with previous Caesarean delivery. Am J Obstet Gynaecol 2000;183:1176-79. (Class B)
Renou P, Chang A, Anderson I, Wood C. Controlled trial of fetal intensive care. Am J Obstet Gynecol 1976;126:470-76. (Class A)
Rinehart BK, Terrone DA, Barrow H, et al. Randomized trial of intermittent or continuous amnioinfusion for variable decelerations. Obstet Gynecol 2000;96:571-74. (Class A)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
38
Rogers R, Gilson G, Kammer-Doak D. Epidural analgesia and active management of labor: effects on length of labor and mode of delivery. Obstet Gynecol 1999;93:995-98. (Class C)
Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the preven-tion of cerebral palsy. N Engl J Med 2008;359:895-905. (Class A)
Rouse DJ, Owen J, Savage KG, Hauth JC. Active phase labor arrest: revisiting the 2-hour minimum. Obstet Gynecol 2001;98:550-54. (Class D)
Sadler LC, Davison T, McCowan LME. A randomised controlled trial and meta-analysis of active management of labour. Br J Obstet Gynaecol 2000;107:909-15. (Class A)
Sakala EP, Kaye S, Murray RD, Munson LJ. Oxytocin use after previous Caesarean: why a higher rate of failed labor trial? Obstet Gynecol 1990;75:356-59. (Class C)
Sanchez-Ramos L, Kaunitz AM, Gaudier FL, et al. Efficacy of maintenance therapy after acute tocolysis: a meta-analysis. Am J Obstet Gynecol 1999;181:484-90. (Class M)
Saunders N, Paterson CM, Wadsworth J. Neonatal and maternal morbidity in relation to the length of the second stage of labour. Br J Obstet Gynaecol 1992;99:381-85. (Class B)
Schmidt S, Koslowski S, Sierra F, et al. Clinical usefulness of pulse oximetry in the fetus with non-reas-suring heart rate pattern? J Perinat Med 2000;28:298-305. (Class C)
Shields SG, Ratcliffe SD, Fontaine P, Leeman L. Dystocia in nulliparous women. Am Fam Phys 2007;75:1671-78. (Class R)
Silver RK, Gibbs RS. Predictors of vaginal delivery in patients with a previous Caesarean section, who require oxytocin. Am J Obstet Gynecol 1987;156:57-60. (Class D)
Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med 2007;357:477-87. (Class R)
Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. Obstet Gynecol 2002;99:129-34. (Class M)
Smith CV. Reversing acute intrapartum fetal distress using tocolytic drugs. Clin Obstet Gynecol 1991;34:352-59. (Class D)
Smith CV, Nguyen HN, Phelan JP, et al. Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations. Am J Obstet Gynecol 1986;155:726-28. (Class D)
SOGC Clinical Practice Guidelines. Guidelines for vaginal birth after previous Caesarean birth. Intl J Gynecol Obstet 2005;89:319-31. (Class R)
Stanley FJ, Crowther C. Atnenatal magnesium sulfate for neuroprotection before preterm birth? N Engl J Med 2008;359:962-64. (Class R)
Stovall TG, Shaver DC, Solomon SK, Anderson GD. Trial of labor in previous Caesarean section patients, excluding classical Caesarean sections. Obstet Gynecol 1987;70:713-17. (Class D)
Strong TH, Vega JS, O'Shaughnessy MJ, et al. Amnioinfusion among women attempting vaginal birth after Caesarean delivery. Obstet Gynecol 1992;79:673-74. (Class D)
Tebes CC, Lynch C, Sinnott J. The effect of treating bacterial vaginosis on preterm labor. Infect Dis Obstet Gynecol 2003;11:123-29. (Class R)
Thorp JM, Hartmann KE, Berkman ND, et al. Antibiotic therapy for the treatment of preterm labor: a review of the evidence. Am J Obstet Gynecol 2002;186:587-92. (Class M)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
39
Thorp JA, Jones AMH, Hunt C, Clark R. The effect of multidose antenatal betamethasone on maternal and infant outcomes. Am J Obstet Gynecol 2001;184:196-202. (Class A)
Towers CV, Bonebrake R, Padilla G, Rumney P. The effect of transport on the rate of severe intraven-tricular hemorrhage in very low birthweight infants. Obstet Gynecol 2000;95:291-95. (Class C)
Turner MJ, Brassil M, Gordon H. Active management of labor associated with a decrease in the Caesarean delivery rate in nulliparas. Obstet Gynecol 1988;71:150-54. (Class C)
Vendittelli F, Volumenie J. Transvaginal ultrasonography examination of the uterine cervix in hospitalised women undergoing preterm labour. Eur J Obstet Gynecol Reprod Biol 2000;90:3-11. (Class R)
Vintzileos AM, Antsaklis A, Varvarigos I, et al. A randomized trial of intrapartum electronic fetal heart rate monitoring versus intermittent auscultation. Obstet Gynecol 1993;81:899-907. (Class A)
Vintzileos AM, Nochimson DJ, Guzman ER, et al. Intrapartum electronic fetal heart rate monitoring versus intermittent auscultation: a meta-analysis. Obstet Gynecol 1995;85:149-55. (Class M)
Yeast JD, Poskin M, Stockbauer JW, Shaffer S. Changing patterns in regionalization of perinatal care and the impact on neonatal mortality. Am J Obstet Gynecol 1998;178:131-35. (Class C)
Zhang J, Troendle JF, Yancey MK. Transactions of the twenty-second annual meeting of the society for maternal-fetal medicine: reassessing the labor curve in nulliparous women. Am J Obstet Gynecol 2002;187:824-28. (Class C)
Management of Labor References Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
40
Conclusion Grading Worksheet A – Annotation #20 (Bacterial Vaginosis)
Management of Labor Third Edition/May 2009
Work
Grou
p's
Con
clu
sion
: T
reat
men
t of
bac
teri
al v
agin
osi
s in
fect
ion i
n p
regnant
wom
en a
t hig
h r
isk f
or
pre
term
del
ivery
by
trad
itio
nal
sev
en-d
ay c
ours
es o
f th
erap
y e
arly
in p
regnan
cy a
ppea
rs t
o r
educe
pre
term
del
iver
y.
Con
clu
sio
n G
rad
e:
II
Work
Grou
p's
Con
clu
sion
: T
he
evid
ence
reg
ardin
g t
reat
men
t of
low
-ris
k,
pre
gnan
t w
om
en w
ith a
sym
pto
mat
ic b
acte
rial
vag
i-nosi
s is
lim
ited
by u
se o
f in
adeq
uat
e th
erap
y i
n t
he
avai
lable
stu
die
s.
Con
clu
sio
n G
rad
e:
Gra
de
Not
Ass
ignab
le
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Mo
rale
s,
Sch
orr
, &
Al-
bri
tto
n (
19
94
)
RC
T
A
ø
-Wo
men
wit
h a
sin
gle
ton
ges
ta-
tio
n a
t 1
3-2
0 w
eek
s; p
rete
rm d
e-li
ver
y i
n p
reced
ing
pre
gn
ancy
;
po
siti
ve
for
BV
; n
o e
vid
ence
of
tric
ho
mo
na
infe
cti
on
-E
xcl
ud
ed:
con
gen
ital
ano
ma-
lies
; si
gn
ific
ant
mate
rnal
com
-p
licati
on
s; d
ocu
men
ted
co
cain
e
use
; in
com
pete
nt
cer
vix
lik
ely
; p
rio
r d
ocu
men
ted
in
tra-
am
nio
tic
or
uri
nar
y t
ract
infe
ctio
n r
esu
lt-
ing
in
pre
term
bir
th;
2n
d t
rim
es-
ter
ble
edin
g,
asy
mp
tom
atic
bac
-te
riu
ria
on
in
itia
l sc
reen
-R
and
om
ized
to
rece
ive
25
0 m
g
met
ron
idaz
ole
(3
X/d
ay f
or
7
day
s) o
r v
itam
in C
tab
let
-Pat
ien
ts i
n P
TL
rec
eiv
ed I
V
mag
nes
ium
su
lfate
an
d,
if t
hat
fa
iled
, o
ral
ind
om
eth
acin
(m
ain
-ta
ined
on
ora
l te
rbu
tali
ne)
-94
en
roll
ed:
14
su
bse
qu
entl
y e
xclu
ded
fro
m a
naly
-si
s (5
lo
st t
o f
oll
ow
-up
, 6
fai
led
to
co
mp
lete
tre
at-
men
t, 3
req
uir
ed t
reatm
ent
for
ren
al
or
pu
lmo
nar
y
dis
eas
e)
-44
of
the
rem
ain
ing
80
wer
e tr
eat
ed w
ith
metr
oni-
daz
ole
, 3
6 w
ith
pla
ceb
o
-Gro
up
s w
ere
sim
ilar
at
bas
eli
ne i
n a
ge, p
arit
y, ra
ce,
sm
ok
ing
sta
tus,
sp
on
tan
eou
s ab
ort
ion
s, p
rete
rm
bir
ths,
ou
tco
me o
f p
enu
ltim
ate
pre
gn
ancy
, fi
rst
tri-
mes
ter
ble
edin
g
-Metr
on
idazo
le g
rou
p h
ad f
ewer
ho
spit
al
adm
issi
on
s fo
r p
rete
rm l
abo
r, f
ewer
wit
h >
1 h
osp
ital
adm
issi
on
, fe
wer
wit
h g
esta
tio
nal
ag
e a
t d
eliv
ery
of
<3
7 w
eek
s,
few
er w
ith
bir
th w
eig
ht
<2
50
0g
, an
d f
ewer
wit
h
PR
OM
(al
l p
<0
.05
)
-In
a v
ery
hig
h-r
isk
gro
up
of
pati
ents
wit
h a
p
rem
atu
re d
eliv
ery
in
th
e p
rece
din
g p
reg
-n
ancy
, th
e t
reatm
ent
of
bac
teri
al
vag
ino
sis
and
per
hap
s ele
vate
d v
agin
al p
H i
n t
he
sec-
on
d t
rim
este
r w
ou
ld r
esu
lt i
n a
su
bst
anti
al
red
uct
ion
of
recu
rren
t p
rete
rm b
irth
s fr
om
ei
ther
id
iop
ath
ic p
rete
rm l
abo
r o
r P
RO
M.
NO
TE
S:
did
sam
ple
siz
e e
stim
atio
n –
wit
h
40
% r
isk
of
pre
mat
uri
ty, a s
amp
le s
ize o
f 4
5
per
gro
up
was
nee
ded
to
dete
ct
at
leas
t a
40
% r
edu
cti
on
in
pre
matu
rity
wit
h 8
0%
p
ow
er a
t 0
.05
lev
el
Institute for Clinical Systems Improvement
www.icsi.org
41
Conclusion Grading Worksheet A – Management of Labor Annotation #20 (Bacterial Vaginosis) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
McG
reg
or,
et
al.
(19
95
) N
on
R
an-
do
m
C
ø
-Wo
men
in
itia
tin
g p
ren
atal
car
e -P
has
e I-
ob
serv
atio
n:
7 m
on
ths,
w
om
en e
xam
ined
fo
r p
anel
of
low
er r
epro
du
ctiv
e tr
act
mic
ro-
org
anis
ms
& s
ele
cted
vag
inal
enzy
mes
at
1st p
ren
atal
vis
it, 2
2-
29
wk
s g
esta
tio
n,
afte
r 3
2 w
ks
ges
tati
on
; tr
eat
men
t p
rov
ided
fo
r N
. g
on
orr
hea
, C
. tr
ach
om
a-
tis,
sy
ph
ilis
, &
uri
nar
y t
ract
in
-fe
ctio
n;
no
tre
atm
ent
un
less
co
mp
lain
ts o
r sy
mp
tom
s fo
r B
V,
T.
vag
ina
lis,
an
d y
eas
t -P
has
e II
: 8
mo
nth
s; i
den
tical
scre
enin
g a
nd
sam
pli
ng
, tr
eat
-m
ent
for
N. g
on
orr
hea
, C
. tr
a-
cho
ma
tis,
T.
vag
ina
lis,
BV
, y
east
& g
rou
p B
str
epto
cocc
al
bac
teri
uri
a
-Tre
atm
ent
of
BV
was
clin
-d
amy
cin
(3
00
mg
ora
lly
2X
/day
for
7 d
ays)
-61
4 e
nro
lled
in
Ph
ase
I, 6
40
in
Ph
ase
II;
anal
ysi
s b
ased
on
55
9 i
n P
has
e I
, 5
79
in
Ph
ase I
I (s
ee
NO
TE
S)
-Ph
ase
I an
d I
I g
rou
ps
wer
e s
imil
ar i
n a
ge,
eth
nic
ity
, m
arit
al
stat
us,
med
ical
his
tory
, sm
ok
ing
, d
rug
use
&
ante
nat
al f
act
ors
; B
V w
as p
rese
nt
in 3
1%
of
Ph
ase I
an
d 3
4%
of
Ph
ase
II p
atie
nts
-Sp
on
tan
eou
s ab
ort
ion
s at
<2
2 w
ks
occ
urr
ed i
n 2
%
of
Ph
ase I
an
d 3
% o
f P
has
e II
pat
ien
ts;
asso
cia
ted
w
ith
BV
at
enro
llm
ent
(RR
=3
.1, 9
5%
CI:
1.4
-6.9
) -P
rete
rm b
irth
in
13
% o
f P
hase
I a
nd
10
% o
f P
has
e II
pat
ien
ts (
NS
) b
ut
rate
of
pre
term
bir
th a
fter
id
io-
pat
hic
pre
term
lab
or
was
red
uce
d i
n P
has
e II
(R
R=
0.4
8;
95
%C
I: 0
.27
-0.8
8)
-Bir
thw
eig
hts
an
d r
ate
s o
f p
rete
rm b
irth
aft
er P
RO
M
or
for
med
ical
com
pli
cati
on
s d
id n
ot
dif
fer
-Ph
ase
I:
BV
ass
ocia
ted
wit
h i
ncr
eas
ed r
isk
of
pre
-te
rm b
irth
(R
R=
1.9
; 9
5%
CI:
1.2
-3.0
) &
pre
term
P
RO
M (
RR
=3
.5;
95
%C
I 1
.4-8
.9)
-Ph
ase
II p
ati
ents
had
red
uce
d r
ates
of
pre
term
bir
th
(vs.
Ph
ase
I, p
=0
.02
)
-In
Ph
ase I
(ri
sk o
f p
rete
rm b
irth
), w
ith
T.
vag
ina
lis
on
ly,
RR
=1
.4;
wit
h B
V o
nly
, R
R=
2.1
; w
ith
T.
vag
i-n
ali
s an
d B
V,
RR
=3
.3
-Tre
atm
ent
of
BV
(p
has
e II
) re
du
ced
ris
ks
of
pre
-te
rm b
irth
(2
5%
) to
rat
es s
imil
ar t
o t
ho
se a
mo
ng
B
V-n
egati
ve
wo
men
wit
h a
pri
or
pre
term
bir
th
-Mu
ltip
le l
og
isti
c r
egre
ssio
n i
nd
icate
d t
hat
BV
(OR
=1
.6;
95
%C
I: 1
.1-2
.4)
was
ass
ocia
ted
wit
h r
isk
o
f p
rete
rm b
irth
-O
ral
clin
dam
yci
n w
as e
ffec
tiv
e fo
r 9
3%
of
wo
men
w
ith
BV
at
the 2
-4 w
k f
oll
ow
-up
-Wo
men
wit
h B
V h
ad i
ncr
ease
d o
ccu
rren
ces
o
f sp
on
tan
eou
s p
reg
nan
cy l
oss
, p
rete
rm
PR
OM
, id
iop
ath
ic p
rete
rm b
irth
, an
d o
ver
all
p
rete
rm b
irth
. S
yst
em
ati
c cl
inic
al
scre
enin
g
and
sta
nd
ard
ized
tre
atm
ent
of
wo
men
wit
h
BV
wer
e a
sso
ciate
d w
ith
a 5
0%
red
ucti
on
in
b
oth
pre
term
bir
th a
nd
pre
term
PR
OM
.
NO
TE
S:
did
sam
ple
siz
e e
stim
atio
n –
wit
h
pre
term
bir
th r
ate
of
13
%,
esti
mate
d t
hat
56
4
wo
men
wo
uld
nee
d t
o b
e st
ud
ied
in
eac
h
ph
ase
to d
ete
ct
a 5
0%
red
ucti
on
in
th
e r
ate
of
pre
term
bir
th w
ith
po
wer
of
80
% a
t 0
.05
lev
el;
ex
clu
ded
th
ose
wit
h n
o p
reg
nan
cy
ou
tco
me d
ata
; al
so e
xcl
ud
ed 3
wh
o h
ad
ther
apeu
tic
abo
rtio
ns
(Ph
ase
I),
1 n
on
pre
g-
nan
t w
om
an (
Ph
ase I
I), w
om
en w
ith
mu
lti-
ple
ges
tati
on
s (4
Ph
ase
I, 1
3 P
hase
II)
; lo
st
or
exclu
ded
pati
ents
dif
fere
d f
rom
th
ose
in
fi
nal
an
aly
sis
in e
thn
ic g
rou
p, 1
st t
rim
este
r
ble
edin
g, re
po
rt o
f tr
aum
a o
r in
jury
du
rin
g
pre
gn
ancy
, ea
rlie
r en
roll
men
t fo
r p
ren
atal
ca
re
Institute for Clinical Systems Improvement
www.icsi.org
42
Conclusion Grading Worksheet A – Management of Labor Annotation #20 (Bacterial Vaginosis) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
McD
on
ald
, et
al.
(19
97
) R
CT
A
–
-S
cree
ned
fo
r B
V f
lora
(G
. va
gi-
na
lis)
an
d B
V a
t 1
6-2
6 w
eek
s at
4 S
ou
th A
ust
rali
a p
erin
ata
l ce
n-
ters
; as
ym
pto
mati
c w
om
en w
ere
inv
ited
to
en
roll
-R
and
om
ized
to
pla
ceb
o o
r o
ral
met
ron
idaz
ole
(4
00
mg
, 2
X/d
ay
for
2 d
ays)
-E
xcl
ud
ed:
mu
ltip
le p
reg
nan
cy,
< 1
7 y
rs o
ld,
in v
itro
fer
tili
za-
tio
n,
all
erg
y t
o m
etr
on
idazo
le,
sym
pto
mat
ic B
V, ru
ptu
red
m
emb
ran
es,
cer
vic
al
cerc
lag
e,
insu
lin
-dep
end
ent
dia
bete
s, p
la-
cen
ta p
raev
ia,
anti
bio
tic
tx f
or
vag
init
is i
n p
ast
2 w
ks,
lan
gu
age
dif
ficu
ltie
s, u
nab
le t
o a
tten
d
clin
ic a
fter
4 w
ks
of
tx
-9,4
07
wer
e sc
reen
ed;
2,4
90
wer
e p
osi
tiv
e; 1
,73
4
wer
e el
igib
le f
or
enro
llm
ent;
87
9 (
51
%)
wer
e en
-ro
lled
-4
39
rec
eiv
ed m
etr
on
idazo
le;
44
0 r
ecei
ved
pla
ceb
o
-Gro
up
s si
mil
ar a
t b
asel
ine
in r
ace,
mate
rnal
ag
e a
t en
roll
men
t, l
ow
so
cio
eco
no
mic
sta
tus,
pri
mi-
gra
vid
a, p
rev
iou
s p
rete
rm b
irth
, g
est
atio
n;
mo
re <
20
yrs
at
enro
llm
ent
in p
lace
bo
gro
up
(p
<0
.01
) -C
om
pli
ance
81
% i
n t
reat
men
t g
rou
p, 8
3%
in
pla
-ce
bo
gro
up
; 1
89
in
tre
atm
ent
gro
up
an
d 2
36
in
pla
-ce
bo
gro
up
to
ok
sec
on
d c
ou
rse
of
treatm
ent;
11
in
tr
eatm
ent
gro
up
an
d 1
6 i
n p
laceb
o g
rou
p b
ecam
e sy
mp
tom
atic
(&
giv
en a
7-d
ay c
ou
rse o
f tr
eatm
ent)
-C
um
ula
tiv
e e
ffic
acy
of
metr
on
idazo
le f
or
treat
men
t
of
BV
was
75
%
-Pre
term
bir
th (
<3
7 w
ks)
in
7.2
% o
f m
etr
on
idazo
le
gro
up
an
d 7
.5%
of
pla
ceb
o g
rou
p;
for
spo
nta
neo
us
pre
term
bir
th, v
alu
es w
ere 4
.7%
an
d 5
.6%
; fo
r P
RO
M,
valu
es w
ere
2.8
% a
nd
3.3
%
-In
su
bse
t o
f 4
80
wo
men
wit
h B
V o
nly
– n
o d
iffe
r-en
ce i
n p
rete
rm b
irth
rate
, sp
on
tan
eou
s p
rete
rm b
irth
rate
or
PR
OM
rat
e -I
n s
ub
set
of
46
wo
men
wit
h p
rev
iou
s p
rete
rm b
irth
, m
etro
nid
azo
le g
rou
p h
ad l
ow
er r
ate
of
spo
nta
neo
us
pre
term
bir
th (
OR
=0
.14
, 9
5%
CI:
0.0
1-0
.84
) -N
o d
iffe
ren
ces
in n
um
ber
s o
f in
fan
ts r
equ
irin
g I
CU
ad
mis
sio
n o
r d
ura
tio
n o
f n
urs
ery
sta
y
-No
dif
fere
nce
in
rep
ort
ing
of
sid
e ef
fects
-Metr
on
idazo
le t
reat
men
t o
f w
om
en w
ith
a
hea
vy
gro
wth
of
G.
vag
ina
lis
or
BV
did
no
t re
du
ce t
he p
rete
rm b
irth
rate
. A
mo
ng
w
om
en w
ith
pre
vio
us
pre
term
bir
th,
trea
t-m
ent
red
uced
th
e ri
sk o
f sp
on
tan
eou
s p
re-
term
bir
th.
NO
TE
S:
att
emp
ted
to
do
scr
een
ing
at
18
w
ks,
en
roll
at
24
wk
s, t
est-
of-
cure
at
28
wk
s,
seco
nd
co
urs
e at
29
wk
s (i
f n
eed
ed),
an
d f
ol-
low
-up
at
32
-36
wk
s (u
nle
ss d
eliv
ery
alr
ead
y
occ
urr
ed);
did
sam
ple
siz
e e
stim
atio
n –
wit
h
exp
ecte
d 3
8%
hig
her
pre
term
bir
th r
ate
th
an
ov
eral
l p
op
ula
tio
n, 1
,32
8 w
om
en w
ere
nee
ded
; an
in
teri
m a
naly
sis
at 8
79
wo
men
in
dic
ated
th
at
the
dif
fere
nce
in
pre
term
bir
th
rate
was
low
er t
han
ex
pect
ed r
equ
irin
g a
sa
mp
le s
ize 1
0 t
imes
lar
ger
(n
ot
feasi
ble
);
wit
h 8
79
en
roll
ed,
26
% p
ow
er t
o d
ete
ct a
3
8%
red
ucti
on
sp
on
tan
eou
s p
rete
rm b
irth
ra
te;
analy
sis
was
by
in
ten
tio
n t
o t
reat
Wo
rk G
rou
p’s
Co
mm
ents
: t
he s
creen
ing
w
as
do
ne l
ate
r in
th
e p
reg
na
ncy
tha
n r
ec-
om
men
ded
an
d t
he
met
ron
ida
zole
do
se w
as
low
er t
ha
n t
he
reco
mm
end
ed d
ose
of
25
0 m
g
ora
lly,
3X
/da
y,
for
7 d
ays
Institute for Clinical Systems Improvement
www.icsi.org
43
Conclusion Grading Worksheet A – Management of Labor Annotation #20 (Bacterial Vaginosis) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Car
ey,
et a
l.
(20
00
) R
CT
A
ø
-S
cree
ned
w
om
en b
etw
een
8
wk
s an
d 2
2 w
ks,
6 d
ays
of
ges
-ta
tio
n f
or
BV
an
d T
. va
gin
ali
s -E
xcl
ud
ed:
sy
mp
tom
s o
f B
V;
alle
rgy
to
met
ron
idaz
ole
; ab
use
o
f et
han
ol;
an
tib
ioti
c t
her
apy
in
p
ast
14
day
s; i
nte
nti
on
to
re-
ceiv
e fu
ture
car
e at
dif
fere
nt
lo-
cati
on
; cu
rren
t o
r p
lan
ned
cer
vi-
cal
cer
cla
ge
or
toco
lyti
c th
er-
apy
; p
rete
rm l
abo
r b
efo
re
scre
enin
g;
feta
l d
eat
h o
r li
fe-
thre
ate
nin
g a
no
mal
y;
mu
ltif
etal
g
esta
tio
n;
med
ical
ill
nes
s re
qu
ir-
ing
ex
ten
siv
e d
rug
th
erap
y
-Ran
do
miz
ed t
ho
se w
ith
BV
o
nly
an
d p
reg
nan
cies
bet
wee
n
16
wk
s an
d 2
3 w
ks,
6 d
ays
-Ran
do
miz
ed t
o 2
g m
etro
nid
a-zo
le o
r p
laceb
o (
2 d
ose
s 4
8 h
rs
apar
t);
foll
ow
-up
at
24
wk
s to
29
wk
s, 6
day
s w
ith
seco
nd
tr
eatm
ent
(2 d
ose
s) r
egar
dle
ss o
f te
st r
esu
lts
-21
,96
5 w
ere
scre
ened
; 6
,54
0 h
ad B
V o
nly
; 1
,95
3
wer
e ra
nd
om
ized
-C
om
pli
ance
mo
nit
ore
d a
fter
1st 3
do
ses
on
ly –
79
%
of
metr
on
idazo
le g
rou
p a
nd
82
% o
f p
laceb
o h
ad
tak
en t
he
full
do
se;
90
% r
etu
rned
fo
r fo
llo
w-u
p v
isit
-O
utc
om
e d
ata
av
aila
ble
fo
r 9
8%
: n
o d
iffe
ren
ce i
n
freq
uen
cy o
f d
eli
ver
y a
t <
37
wk
s g
esta
tio
n (
or
de-
liv
ery
bef
ore
35
or
32
wk
s);
no
dif
fere
nces
wit
h r
e-g
ard
to
lo
w b
irth
wei
gh
t, v
ery
lo
w b
irth
weig
ht,
or
pre
term
deli
ver
y a
ttri
bu
tab
le t
o s
po
nta
neo
us
lab
or
or
spo
nta
neo
us
rup
ture
of
the m
em
bra
nes
-Of
tho
se w
ith
fo
llo
w-u
p t
esti
ng
, 2
2%
in
metr
on
ida-
zole
gro
up
an
d 6
3%
in
pla
ceb
o g
rou
p s
till
had
BV
-N
o d
iffe
ren
ce i
n a
dm
issi
on
s to
ho
spit
al
for
pre
term
lab
or
or
pre
term
PR
OM
, re
ceip
t o
f to
coly
tic
dru
gs,
v
agin
al
infe
cti
on
s re
qu
irin
g t
reatm
ent,
cli
nic
al
in-
traa
mn
ioti
c in
fecti
on
or
po
stp
artu
m e
nd
om
etr
itis
-N
o d
iffe
ren
ce i
n p
assa
ge
of
meco
niu
m, fe
tal
dea
th
or
neo
nat
al d
eath
, ad
mis
sio
n t
o N
ICU
or
pre
sen
ce
of
neo
nat
al s
epsi
s
-Tre
atm
ent
of
asy
mp
tom
atic
BV
wit
h m
et-
ron
idaz
ole
did
no
t re
du
ce
the
risk
of
pre
term
d
eliv
ery
in
wo
men
at
low
ris
k f
or
pre
term
d
eliv
ery
or
wo
men
wit
h a
his
tory
of
pre
term
d
eliv
ery
. N
OT
ES
: s
ho
rt c
ou
rse o
f tr
eatm
ent
was
cho
-se
n t
o i
mp
rov
e co
mp
lian
ce
Wo
rk G
rou
p’s
Co
mm
ents
: t
he s
creen
ing
w
as
do
ne l
ate
r in
th
e p
reg
na
ncy
tha
n r
ec-
om
men
ded
an
d t
he
met
ron
ida
zole
do
se w
as
low
er t
ha
n t
he
reco
mm
end
ed d
ose
of
25
0 m
g
ora
lly,
3X
/da
y,
for
7 d
ays
Institute for Clinical Systems Improvement
www.icsi.org
44
Conclusion Grading Worksheet B – Annotation #66(Management of Protracted Labor)
Management of Labor Third Edition/May 2009
Work
Grou
p's
Con
clu
sion
: A
ctiv
e m
anag
emen
t of
labo
r does
not
reduce
the
rate
of
Cae
sare
an d
eliv
ery b
ut
may
dec
reas
e th
e le
ngth
of
labor
and i
ncr
ease
pat
ient
sati
sfac
tion i
n n
ull
ipara
s.
Con
clu
sio
n G
rad
e:
II
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Nai
den
&
Des
hp
and
e
(20
01
)
Cas
e S
erie
s D
–
-D
eliv
ery
sta
tist
ics
for
10
-yr
pe-
rio
d a
s o
bta
ined
fro
m b
irth
lo
g-
bo
ok
; p
rio
r to
dat
a co
llect
ion
p
erio
d s
taff
ag
reed
wit
h g
oal
of
few
er o
per
ativ
e d
eli
ver
ies;
th
ose
w
ith
hig
her
rat
es r
evie
wed
lit
-er
atu
re;
eac
h p
rov
ider
giv
en
ow
n d
eliv
ery
sta
tist
ics
-Sta
ff a
lso
ag
reed
on
pro
toco
ls*
for
acti
ve m
anag
em
ent
of
lab
or
-VB
AC
was
en
cou
rag
ed
-Nu
rsin
g s
taff
mai
nta
ined
bir
th
log
bo
ok
(m
ater
nal
info
rmat
ion
an
d c
om
pli
cati
on
s, l
abo
r in
for-
mat
ion
, fe
tal
info
rmat
ion
); d
ata
also
co
llecte
d o
n C
aesa
rean
de-
liv
ery
rate
fo
r 5
yrs
pri
or
to
stu
dy
-N
eon
atal
mo
rbid
ity
: b
irth
tr
aum
a, p
rese
nce
of
thic
k m
eco
-n
ium
, lo
w A
PG
AR
sco
re (
<6
at
5 m
in),
per
inat
al d
eat
h
-27
,78
0 d
eliv
erie
s in
10
yrs
; 3
,18
6 w
ere C
aesa
rean
-R
isk
fact
ors
fo
r C
aesa
rean
st
able
th
rou
gh
ou
t st
ud
y
per
iod
(%
of
nu
llip
aro
us
bir
ths,
ag
e <
19
yrs
, ag
e >
35
yrs
, m
ult
iple
ges
tati
on
s, b
irth
wei
gh
t <
2,5
00
g,
bir
th w
eig
ht
>4
,00
0 g
, g
esta
tio
nal
age
<3
7 w
ks,
ges
-ta
tio
nal
age >
41
wk
s)
-% M
edic
aid
deli
ver
ies
rem
ain
ed a
t ap
pro
xim
ate
ly
66
%;
% o
f H
isp
anic
-su
rnam
e p
ati
ents
in
creas
ed
fro
m 3
5%
in
19
89
to
50
% i
n 1
99
8
-Caes
area
n d
eliv
ery
rat
es:
19
89
19
98
T
ota
l 1
6.6
%
10
.9%
P
rim
ary
9
.2%
7
.1%
R
epea
t d
eli
ver
ies
7.4
%
3.8
%
Nu
llip
aro
us
16
.4%
1
1.9
%
Mu
ltip
aro
us
16
.8%
1
0.5
%
-Sig
nif
ican
t d
ecr
eas
e i
n r
ate
of
Cae
sare
an d
eliv
ery
for
cep
halo
pel
vic
dis
pro
po
rtio
ns
(p<
0.0
01
); d
e-cr
ease
s fo
r o
ther
in
dic
ati
on
s w
ere
no
t si
gn
ific
ant
-Sig
nif
ican
t in
creas
es (
p<
0.0
01
): o
xy
tocin
use
, in
-st
rum
ente
d v
agin
al d
eliv
ery
, an
d e
pid
ura
l an
esth
esia
-N
o s
ign
ific
ant
chan
ges
in n
eon
ata
l m
orb
idit
y r
ate,
p
erin
ata
l an
d n
eon
ata
l m
ort
ali
ty r
ates
, o
r n
um
ber
of
stil
lbir
ths
-In
10
-yea
r st
ud
y p
erio
d,
Cae
sare
an d
eli
ver
y
rate
s w
ere
low
ered
sig
nif
ican
tly
wh
ile n
ot
adv
erse
ly i
ncr
eas
ing
in
dic
ato
rs o
f p
erin
atal
m
orb
idit
y o
r d
eat
h.
Mo
st o
f th
e r
edu
cti
on
w
as d
ue t
o i
ncr
easi
ng
th
e a
cti
ve
man
age-
men
t o
f la
bo
r an
d t
o e
nco
ura
gin
g V
BA
C d
e-li
ver
ies.
NO
TE
S:
*p
roto
col
cal
led
fo
r o
xy
tocin
in
fu-
sio
n o
nly
un
der
su
per
vis
ion
of
atte
nd
ing
p
hy
sici
an;
on
ly a
llo
wed
nu
rses
wit
h e
xp
eri-
ence
in
lab
or
and
deli
ver
y a
nd
ass
essm
ent
of
feta
l h
eart
rate
patt
ern
s an
d i
nit
ial
man
age-
men
t o
f ab
no
rmal
pat
tern
s to
pra
cti
ce
the
pro
toco
l
Institute for Clinical Systems Improvement
www.icsi.org
45
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Sad
ler,
Dav
i-so
n, &
M
cCo
wan
(2
00
0)
RC
T
A
ø
-In
clu
ded
: n
ull
ipar
ou
s; s
ing
le-
ton
pre
gn
ancy
, n
o s
ever
e c
ar-
dia
c d
isea
se, n
o u
teri
ne
scar
, n
o
pro
ven
co
ntr
act
ed p
elv
is
-Ex
clu
ded
: i
nd
uced
lab
or;
no
n-
cep
hali
c p
rese
nta
tio
n;
ges
tati
on
<
37
wk
s, a
bn
orm
al
card
ioto
cog
-
rap
hy
or
thic
k m
eco
niu
m,
ele
c-ti
ve C
aes
area
n;
intr
aute
rin
e d
eath
, m
ult
ipar
ity
-R
and
om
ized
to
act
ive o
r ro
u-
tin
e m
gm
t o
f la
bo
r -A
ctiv
e m
gm
t g
rou
p e
nco
ura
ged
to
hav
e a
mn
ioto
my
at
dia
gn
osi
s
of
lab
or;
cer
vic
al
ass
ess
men
t ev
ery
2 h
rs;
ox
yto
cin
if
pro
gre
ss
del
ayed
; n
o p
roto
col
for
rou
tin
e m
gm
t -D
id m
eta-
analy
sis
of
4 s
tud
ies
of
acti
ve
vs.
ro
uti
ne
mg
mt
(in
-cl
ud
ing
pre
sen
t st
ud
y)
-32
0 r
and
om
ized
to
act
ive m
gm
t an
d 3
31
to
ro
uti
ne;
no
dif
fere
nces
at
base
lin
e; m
ore
wo
men
in
th
e a
ctiv
e
mg
mt
gro
up
had
am
nio
tom
y (
72
% v
s. 6
3%
; p
<0
.05
) an
d a
t lo
wer
dil
atat
ion
(5
.1 c
m v
s. 5
.7 c
m;
p=
0.0
06
);
ox
yto
cin
use
d m
ore
co
mm
on
ly (
53
% v
s. 3
9%
; p
<0
.05
) an
d a
t h
igh
er d
ose
s (p
=0
.00
01
) in
acti
ve
mg
mt
gro
up
; n
o d
iffe
ren
ce
in e
pid
ura
l ra
tes
or
nu
m-
ber
rec
eiv
ing
on
e-to
-on
e m
idw
ifer
y
-Lab
or
red
uced
by
50
min
in
acti
ve
mg
mt
gro
up
(fo
r v
agin
al
deli
ver
ies)
; re
du
cti
on
in
fir
st s
tag
e o
f la
bo
r o
nly
; 5
% o
f ac
tiv
e m
gm
t g
rou
p h
ad p
rolo
ng
ed l
abo
r (v
s. 1
2%
of
rou
tin
e m
gm
t; p
<0
.05
) -C
aes
area
n d
eliv
ery
rat
es d
id n
ot
dif
fer
(9%
acti
ve
mg
mt,
10
% r
ou
tin
e m
gm
t);
adju
stm
ent
for
age,
eth
-
nic
ity
, g
esta
tio
nal
ag
e, b
irth
wei
gh
t, e
pid
ura
l u
se,
and
dil
ata
tio
n a
t ra
nd
om
izat
ion
did
no
t al
ter
od
ds
of
Caes
area
n d
eliv
ery
(u
nad
just
ed &
ad
just
ed
OR
s=0
.97
) -N
ewb
orn
ou
tco
mes
did
no
t d
iffe
r -M
ate
rnal
sati
sfact
ion
wit
h l
abo
r ca
re d
id n
ot
dif
fer
-40
% o
f act
ive m
gm
t p
atie
nts
did
no
t ad
her
e to
!1
asp
ect
of
pro
toco
l -M
eta
-an
aly
sis
sho
wed
no
red
ucti
on
in
Cae
sare
an
rate
wit
h a
cti
ve
mg
mt
(OR
=0
.93
; 9
5%
CI:
0.8
-1.0
8)
-Act
ive
man
agem
ent
of
lab
or
red
uced
th
e d
ura
tio
n o
f th
e f
irst
sta
ge
of
lab
or
wit
ho
ut
affe
cti
ng
th
e r
ate
of
Caes
area
n s
ect
ion
, m
a-te
rnal
sati
sfac
tio
n,
or
oth
er m
ater
nal
or
new
-b
orn
mo
rbid
ity
. N
OT
ES
: l
abo
r w
as d
efin
ed a
s co
ntr
act
ion
s o
ccu
rrin
g a
t le
ast
on
ce
ever
y 5
min
s; l
asti
ng
!
40
sec
, w
ith
sp
on
tan
eou
s ru
ptu
re o
f m
em-
bra
nes
or
full
eff
ace
men
t o
f ce
rvix
an
d d
ila-
tati
on
of !
2 c
m;
did
sam
ple
siz
e e
stim
ati
on
–
32
0 p
er a
rm o
f st
ud
y t
o d
etec
t re
du
ctio
n i
n
Caes
area
n r
ate
fro
m 1
8%
to
10
% w
ith
po
wer
=8
0%
; alp
ha=
0.0
5
Institute for Clinical Systems Improvement
www.icsi.org
46
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Fra
ser,
Tu
rco
t,
Kra
uss
, B
ris-
son
-Car
rol
(20
00
)
Sy
s-te
mati
c R
evie
w
M
N/A
-I
ncl
ud
ed:
9 r
and
om
ized
tri
als
com
par
ing
ro
uti
ne
am
nio
tom
y
to a
n a
ttem
pt
to c
on
serv
e th
e
mem
bra
nes
; ca
teg
ori
cal
data
av
aila
ble
on
maj
or
ind
icato
rs o
f m
ater
nal
& n
eon
ata
l m
orb
idit
y;
accep
tab
le m
eth
od
olo
gic
al q
ual
-
ity
, n
o e
vid
ence
of
syst
emat
ic
erro
r in
ran
do
miz
ati
on
or
fol-
low
-up
pro
cess
es;
wo
men
in
sp
on
tan
eou
s la
bo
r
-5 t
rial
s w
ere
nu
llip
aro
us
wo
men
on
ly;
4 w
ere m
ix
of
nu
llip
aro
us
and
mu
ltip
aro
us
-Use
of
ox
yto
cin
var
ied
in
stu
die
s (h
ete
rog
eneit
y)
-Ear
ly u
se o
f am
nio
tom
y l
ead
s to
an
av
erag
e re
duc-
tio
n o
f la
bo
r d
ura
tio
n o
f 6
0-1
20
min
ute
s; l
eng
th o
f la
bo
r (f
rom
ran
do
miz
ati
on
to
deli
ver
y)
was
sig
nif
i-ca
ntl
y r
edu
ced
by
54
min
ute
s in
ear
ly a
mn
ioto
my
gro
up
(N
OT
E:
data
fro
m 3
stu
die
s)
-In
cid
ence
of
dy
sto
cia
was
red
uced
in
th
e am
nio
t-o
my
gro
up
(O
R=
0.6
3)
(NO
TE
: d
ata
fro
m 1
stu
dy
) -T
ren
d t
ow
ard
in
creas
ed r
isk
of
Cae
sare
an w
ith
ea
rly
am
nio
tom
y
-Am
nio
tom
y i
s an
eff
ect
ive m
eth
od
to
sh
ort
en l
abo
r d
ura
tio
n a
nd
red
uce
the f
re-
qu
ency
of
ox
yto
cin
ad
min
istr
atio
n.
Th
ere
was
no
ev
iden
ce o
f ad
ver
se n
eon
ata
l co
nse
-q
uen
ces.
It
wo
uld
see
m r
eas
on
able
to
re-
serv
e am
nio
tom
y f
or
lab
ors
th
at a
re p
ro-
gre
ssin
g s
low
ly.
NO
TE
S:
stu
die
s w
ere
do
ne i
n c
ente
rs w
her
e
a la
rge p
rop
ort
ion
of
mo
ther
s re
ceiv
ed
epid
ura
l an
esth
esia
; co
mp
lian
ce w
ith
th
e co
nse
rvati
ve
app
roach
was
lo
w
Ro
use
, O
wen
, &
Hau
th (
19
99
) C
ase
Ser
ies
D
ø
-Wo
men
!3
6 w
ks
ges
tati
on
wit
h
1)
spo
nta
neo
us
acti
ve
ph
ase l
a-b
or
(dil
ata
tio
n !
4 c
m,
at l
east
2
con
tract
ion
s in
10
min
ute
s) &
2)
lab
or
arre
st ("
1 c
m c
erv
ical
pro
gre
ss i
n 2
hrs
) -E
xcl
ud
ed:
no
nv
erte
x p
rese
nta
-
tio
n;
pre
vio
us
Cae
sare
an d
eliv
-er
y;
mu
ltip
le g
esta
tio
n;
no
n-
reas
suri
ng
FH
R t
raci
ng
, ch
ori
oam
nio
nit
is, o
r sp
on
tan
e-o
us
con
tract
ion
s !
25
0 M
on
tev
i-d
eo u
nit
s at
tim
e o
f la
bo
r ar
rest
-O
xy
toci
n a
dm
inis
tere
d a
t d
iag
-
no
sis
of
acti
ve-
ph
ase l
abo
r ar
-re
st;
Caes
area
n d
eli
ver
y f
or
la-
bo
r ar
rest
do
ne
afte
r 4
hrs
of
ox
yto
cin
wit
h s
ust
ain
ed c
on
trac-
tio
n p
atte
rn >
20
0 M
on
tev
ideo
u
nit
s o
r 6
hrs
ox
yto
cin
reg
ard
-le
ss o
f co
ntr
act
ion
patt
ern
-54
2 e
lig
ible
: 2
88
(5
3%
) n
ull
ipar
ou
s, 2
54
(4
7%
) p
aro
us;
gro
up
s w
ere
sim
ilar
dem
og
rap
hic
all
y
-Vag
inal
deli
ver
y r
ate
92
% o
ver
all
(9
7%
fo
r p
aro
us
gro
up
, 8
8%
fo
r n
ull
ipar
ou
s)
-Vag
inal
deli
ver
y r
ate
s am
on
g t
ho
se w
ith
no
pro
-g
ress
aft
er 2
hrs
of
ox
yto
cin
: 9
1%
fo
r p
aro
us
gro
up
, 7
4%
fo
r n
ull
ipar
ou
s g
rou
p
-Vag
inal
deli
ver
y r
ate
s am
on
g t
ho
se w
ith
no
pro
-g
ress
aft
er 4
hrs
of
ox
yto
cin
: 8
8%
fo
r p
aro
us
gro
up
, 5
6%
fo
r n
ull
ipar
ou
s g
rou
p
-No
ute
rin
e ru
ptu
re o
r h
yst
erect
om
y;
rate
s o
f ch
ori
oam
nio
nit
is (
10
%)
and
en
do
met
riti
s (5
%)
wer
e
hig
her
fo
r n
ull
ipar
as t
han
par
ou
s w
om
en (
bo
th 2
%);
la
bo
r p
rog
ress
(o
r la
ck t
her
eof)
co
rrela
ted
wit
h r
isk
of
mate
rnal
infe
ctio
us
com
pli
cat
ion
s -N
o s
till
bir
ths
or
neo
nat
al d
eath
s; c
om
pli
cat
ion
s d
id
no
t d
iffe
r b
ased
on
wh
eth
er t
her
e w
as l
abo
r p
ro-
gre
ss, n
o p
rog
ress
, o
r n
o e
xam
inat
ion
-4
2 C
aes
area
n d
eliv
erie
s (2
4 l
abo
r ar
rest
, 1
0
no
n-r
eass
uri
ng
feta
l st
atu
s, 8
bo
th l
abo
r ar
rest
an
d
no
n-r
eass
uri
ng
sta
tus)
-Th
e m
anag
emen
t p
roto
col
use
d i
n t
his
stu
dy
re
sult
ed i
n a
hig
h r
ate
of
vag
inal
del
iver
y
(92
%)
wit
h n
o s
ever
e a
dv
erse
mate
rnal
, fe
tal
or
neo
nat
al o
utc
om
es.
Ex
ten
din
g t
he m
ini-
mu
m p
erio
d o
f o
xy
tocin
au
gm
enta
tio
n f
or
acti
ve-
ph
ase
lab
or
fro
m 2
to
at
leas
t 4
ho
urs
w
as e
ffec
tiv
e an
d s
afe.
NO
TE
S:
ox
yto
cin
do
se w
as o
ne
m#
/min
in
-cr
ease
d e
ver
y 1
5 m
in o
ver
2 h
rs t
o
30
m#
/min
; 9
3%
rec
eiv
ed c
on
tin
uo
us
lum
bar
ep
idu
ral
anal
ges
ia
Institute for Clinical Systems Improvement
www.icsi.org
47
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Lav
end
er,
Alf
irev
ic,
&
Wal
kin
shaw
(1
99
8)
Lav
end
er, W
al-
lym
ahm
ed,
&
Wal
kin
shaw
(1
99
9)
RC
T
A
ø
-Pri
mig
rav
idas
wit
h u
nco
mp
li-
cate
d p
reg
nan
cie
s; s
po
nta
neo
us
lab
or
at t
erm
; si
ng
leto
n c
eph
ali
c p
rese
nta
tio
n
-Ran
do
miz
ed t
o h
ave p
rog
ress
o
f la
bo
r re
cord
ed o
n a
par
-to
gra
m w
ith
an
act
ion
lin
e a
t 2
,
3 o
r 4
hrs
; p
rolo
ng
ed l
abo
r d
e-fi
ned
as
pro
gre
ss r
eac
hin
g a
c-ti
on
lin
e; o
bst
etri
c i
nte
rven
tio
n
(am
nio
tom
y a
nd
ox
yto
cin
if
mem
bra
nes
in
tact;
ox
yto
cin
o
nly
if
mem
bra
nes
ru
ptu
red
) tr
igg
ered
by
act
ion
lin
e
-Qu
esti
on
nai
re g
iven
on
sec
on
d
po
stn
atal
day
to
61
8 p
ati
ents
ra
nd
om
ized
in
fir
st y
ear
of
stu
dy
-Fro
m 1
99
8 r
eferen
ce:
-92
8 w
om
en r
and
om
ized
-C
aes
area
n d
eliv
ery
rat
es:
11
.1%
fo
r 2-h
r g
rou
p,
14
.2%
fo
r 3
-hr
gro
up
, &
8.4
% f
or
4-h
r g
rou
p;
sig
-n
ific
ant
dif
fere
nce
(p<
0.0
5)
bet
wee
n 3
an
d 4
hrs
-W
om
en i
n 2
ho
ur
gro
up
mo
re s
ati
sfie
d w
ith
th
eir
la
bo
r th
an (
p<
0.0
00
01
vs.
3 a
nd
4 h
ou
rs)
-Fro
m 1
99
9 r
eferen
ce:
-Dat
a fr
om
51
9 w
ho
ret
urn
ed q
ues
tio
nn
air
e (8
6.5
%
resp
on
se);
res
po
nse
rate
s si
mil
ar i
n t
he
3 g
rou
ps
-No
dif
fere
nce
s in
in
trap
artu
m o
utc
om
es e
xcep
t ac
-ti
on
lin
e cr
oss
ed f
or
50
% o
f 2
-hr
gro
up
an
d 3
7%
of
4-h
r g
rou
p (
p=
0.0
2)
and
in
terv
enti
on
occu
rred
in
4
6%
of
2-h
r g
rou
p a
nd
33
% o
f 4
-hr
gro
up
(p
=0
.02
);
Caes
area
n d
eliv
ery
rat
e d
id n
ot
dif
fer
in t
his
sub
-g
rou
p
-Wo
men
pre
fer
acti
ve m
anag
em
ent
of
lab
or.
E
arli
er i
nte
rven
tio
n m
ay b
e as
soci
ated
wit
h
hig
her
Caes
area
n d
eliv
ery
rat
es.
NO
TE
S:
qu
esti
on
nair
es w
ere
com
ple
ted
an
d
retu
rned
at
the
pati
ent’
s co
nv
enie
nce
Wo
rk G
rou
p’s
Co
mm
ents
: ra
nd
om
iza
tio
n
wa
s d
on
e b
y ca
re p
rovid
ers
in t
he
lab
or
an
d
del
ivery
un
it;
a c
om
men
tary
by
Ha
nn
ah
(B
irth
19
99
;26
:97
-98
) n
ote
d n
on
-sig
nif
ica
nt
dif
fere
nces
bet
ween
gro
up
s in
% w
ith
dil
ata
-
tio
n <
3 c
m a
t ra
nd
om
iza
tio
n a
nd
ep
idu
ral
an
alg
esic
use
Institute for Clinical Systems Improvement
www.icsi.org
48
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Fri
go
lett
o,
Lie
-b
erm
an,
Lan
g,
et a
l. (
19
95
)
RC
T
A
ø
-3,0
28
nu
llip
aro
us
wo
men
eli
gi-
ble
; 1
93
4 (
64
%)
agre
ed t
o p
ar-
tici
pat
e an
d w
ere
ran
do
miz
ed t
o
acti
ve m
gm
t (n
=1
01
7)
or
usu
al
care
(n
=9
17
); d
ata
mis
sin
g f
rom
1
9
-Ran
do
miz
atio
n b
efo
re 3
0 w
ks
ges
tati
on
; el
igib
le p
ati
ents
had
n
o c
on
dit
ion
s as
socia
ted
wit
h
incr
eas
ed r
isk
of
pre
term
or
Caes
area
n d
eliv
ery
-B
oth
gro
up
s: fe
tal
hea
rt r
ate
mo
nit
ori
ng
; ac
cess
to
pain
reli
ef
-Act
ive
mg
mt
gro
up
: c
ared
fo
r
in a
sep
arate
un
it b
y d
iffe
ren
t st
aff;
in
clu
ded
1-t
o-1
nu
rsin
g
care
, st
and
ard
ized
dia
gn
osi
s o
f la
bo
r, a
nd
mg
mt
of
lab
or
(am
ni-
oto
my
wit
hin
1 h
r o
f d
iag
no
sis,
ce
rvic
al
exam
s at
lea
st e
ver
y 2
h
rs, o
xy
tocin
du
rin
g e
ith
er s
tag
e
1 o
r st
age
2 o
f la
bo
r);
in f
inal
p
roto
col
fail
ure
to
pro
gre
ss w
as
fail
ure
of
no
rmal
pro
gre
ss o
f ce
rvic
al
dil
atat
ion
or
seco
nd
st
age
of
>2
hrs
(>
3 h
rs i
f ep
idu
ral
cat
het
er)
-Usu
al C
are G
rou
p:
no
co
n-
stra
ints
on
ph
ysi
cian
s
-In
ten
tio
n-t
o-t
reat
(IT
T)
anal
ysi
s:
all
ran
do
miz
ed
-Pro
toco
l-eli
gib
le s
ub
gro
up
an
aly
sis:
th
ose
med
ical-
ly e
lig
ible
to
rece
ive t
reatm
ent
acco
rdin
g t
o p
roto
col
at t
ime
of
on
set
of
lab
or
-IT
T a
nal
ysi
s:
data
fro
m 1
91
5 p
ati
ents
; C
aes
arean
ra
te w
as
19
.5%
in
act
ive m
gm
t g
rou
p a
nd
19
.4%
in
u
sual
car
e g
rou
p;
resu
lts
un
chan
ged
wh
en a
dju
sted
for
bas
eli
ne
char
act
eris
tics
or
epid
ura
l an
est
hes
ia
use
; C
aesa
rean
rate
s d
ue t
o f
ailu
re t
o p
rog
ress
wer
e 7
% i
n a
ctiv
e m
gm
t an
d 8
% i
n u
sual
car
e g
rou
ps
-Su
bg
rou
p a
nal
ysi
s:
a. 3
3%
of
the a
ctiv
e m
gm
t g
rou
p a
nd
35
% o
f th
e u
sual
car
e g
rou
p d
evelo
ped
med
ical
co
mp
lica
tio
ns
or
had
lab
or
ind
uced
an
d w
ere i
nel
igib
le;
the p
roto
-
col-
eli
gib
le s
ub
gro
up
in
clu
ded
67
8 i
n a
cti
ve
mg
mt
and
58
5 i
n u
sual
car
e;
63
3 i
n a
ctiv
e m
gm
t g
rou
p
wer
e tr
eat
ed a
cco
rdin
g t
o p
roto
col
b. G
rou
ps
did
no
t d
iffe
r at
bas
elin
e c.
Act
ive m
gm
t g
rou
p h
ad m
ore
fre
qu
ent
vag
inal
ex
-am
s, h
ad m
em
bra
nes
rup
ture
d a
rtif
icia
lly
mo
re o
ften
(a
nd
ear
lier
), w
ere m
ore
lik
ely
to
rece
ive o
xy
tocin
,
had
hig
her
max
imal
do
se o
f o
xy
toci
n, re
qu
este
d
epid
ura
l an
esth
esia
les
s o
ften
(p
<0
.05
) d
. O
ver
all
rate
s o
f C
aes
arean
deli
ver
y w
ere
sim
ilar
: 1
0.9
% i
n a
ctiv
e m
gm
t g
rou
p a
nd
11
.5%
in
usu
al
care
gro
up
(R
R=
0.9
); f
or
bo
th g
rou
ps,
rate
of
Cae
-sa
rean
beca
use
of
feta
l d
istr
ess
was
lo
w (
2.2
% i
n a
c-ti
ve m
gm
t g
rou
p a
nd
1.2
% i
n u
sual
care
gro
up
);
sho
rter
lab
or
in a
ctiv
e m
gm
t g
rou
p (
6.2
hrs
vs.
8.9
h
rs)
e. L
ow
er i
ncid
ence
of
mat
ern
al f
ever
in
act
ive
mg
mt
gro
up
(R
R=
0.6
); o
ther
co
mp
lica
tio
ns
wer
e sa
me
for
bo
th g
rou
ps;
no
dif
fere
nces
in
in
fan
ts' o
utc
om
es
-Th
e sa
fety
of
an a
ctiv
e m
anag
em
ent
pro
to-
col
was
co
nfi
rmed
. N
o s
ub
stan
tial
decr
eas
e
in t
he
rate
of
Caes
area
n d
eli
ver
y w
as o
b-
serv
ed.
NO
TE
S:
in
clu
ded
all
co
mp
on
ents
of
pro
to-
col
for
acti
ve
mg
mt
of
lab
or;
im
ple
men
ted
ac
tiv
e m
gm
t w
ith
sep
arate
sta
ff i
n a
ph
ysi
-ca
lly
sep
arat
e d
eliv
ery
un
it;
Haw
tho
rne
ef-
fect
may
hav
e ac
cou
nte
d f
or
resu
lts
(stu
dy
fo
cuse
d o
n r
ate
s o
f C
aesa
rean
deli
ver
y s
o
rate
in
usu
al
care
gro
up
may
hav
e b
een
low
-er
ed)
Institute for Clinical Systems Improvement
www.icsi.org
49
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Ló
pez
-Zen
o,
Pea
cem
an,
Ad
ash
ek,
&
So
col
(19
92
)
RC
T
A
ø
-70
5 n
ull
ipar
ou
s w
om
en i
n
spo
nta
neo
us
lab
or
at !
37
wk
s,
excl
ud
ed m
ult
iple
gest
atio
n,
no
nce
ph
alic
pre
sen
tati
on
an
d
pre
vio
us
ute
rin
e su
rger
y
-Ran
do
mly
ass
ign
ed t
o e
ith
er
acti
ve o
r tr
adit
ion
al m
anag
e-
men
t
-Bo
th g
rou
ps:
fe
tal
hea
rt r
ate
mo
nit
ore
d, fr
eq. an
d i
nte
nsi
ty o
f co
ntr
act
ion
s as
sess
ed b
y t
o-
ko
dy
nam
om
etry
; u
mb
ilic
al-c
ord
ar
teri
al
and
ven
ou
s b
loo
d o
b-
tain
ed a
t d
eli
ver
y
-Act
ive
mg
mt
gro
up
: a
mn
iot-
om
y w
ith
in 1
hr
of
dia
gn
osi
s o
f la
bo
r (i
f m
emb
ran
es i
nta
ct)
; cer
-v
ical
exam
s ev
ery
hr
for
the f
irst
3
hrs
an
d t
hen
ev
ery
2 h
rs;
ox
y-
toci
n i
f ra
te o
f d
ilati
on
was
<1
cm
/hr
in 1
st s
tag
e o
f la
bo
r o
r if
des
cen
t o
f h
ead
was
arr
est
ed f
or
1 h
r in
2n
d s
tag
e -T
rad
. m
gm
t g
rou
p:
am
nio
t-o
my
, fr
eq.
of
cer
vic
al
exam
s,
and
cri
teri
a fo
r in
adeq
uate
pro
-g
ress
wer
e le
ft t
o t
he
ph
ysi
cia
n;
ox
yto
cin
was
use
d f
or
arre
st o
f
pro
gre
ss
-35
1 i
n a
ctiv
e m
gm
t an
d 3
54
in
tra
dit
ion
al
mg
mt
(co
ntr
ol
gro
up
); n
o d
iffe
ren
ces
in b
asel
ine c
har
acte
r-is
tics;
on
ly d
iffe
ren
ce
in c
har
act
eris
tics
of
lab
or
was
m
axim
al
do
se o
f o
xy
tocin
(h
igh
er i
n a
ctiv
e m
gm
t g
rou
p, p
<0
.00
01
) -O
utc
om
es:
A
ctiv
e M
gm
t
T
rad
itio
nal
Mg
mt
Caes
area
n D
eli
ver
y
3
7 (
11
%)
5
0 (
14
%)*
V
agin
al
Del
iver
y
31
4 (
90
%)
3
04
(8
6%
) *
Dif
fere
nce
was
sig
nif
ican
t (p
<0
.05
) af
ter
adju
st-
men
t fo
r p
ote
nti
al c
on
fou
nd
ing
var
iab
les
-Dif
fere
nce
in C
aes
arean
deli
ver
y r
ate
was
du
e p
ri-
mar
ily
to
a d
ecr
eas
e i
n t
he f
req
uen
cy o
f ar
rest
dis
or-
der
s
-Dif
fere
nce
was
gre
ate
r fo
r p
ati
ents
of
pri
vate
ph
ysi
-ci
ans
than
fo
r cl
inic
pati
ents
(1
1%
vs.
16
%)
-On
ly 4
.6%
of
pati
ents
in
act
ive m
gm
t g
rou
p h
ad n
ot
del
iver
ed b
y 1
2 h
ou
rs a
fter
ad
mis
sio
n c
om
par
ed t
o
18
.9%
in
th
e tr
adit
ion
al m
gm
t g
rou
p (
p<
0.0
01
) -N
o i
ncr
eas
e in
co
mp
licat
ion
s o
f la
bo
r in
acti
ve
mg
mt
gro
up
; act
ive m
anag
em
ent
had
gre
ate
r p
ercen
t
of
pat
ien
ts w
ith
ox
yto
cin
decr
ease
d o
r st
op
ped
(p
<0
.05
) an
d l
ow
er p
erce
nt
of
pat
ien
ts w
ith
ch
ori
oam
nio
nit
is (
p<
0.0
1)
-No
dif
fere
nce
s in
neo
nata
l o
utc
om
es
base
d o
n a
rte-
rial
pH
an
d o
ther
blo
od
gas
ind
exes
, b
irth
wei
gh
t,
AP
GA
R s
core
, N
ICU
ad
mis
sio
ns,
seiz
ure
s, d
ays
in
ho
spit
al;
no
in
creas
ed m
orb
idit
y i
n a
cti
ve
mg
mt
case
s
-Act
ive
man
agem
ent
of
lab
or
in n
ull
ipar
ou
s p
atie
nts
was
ass
ocia
ted
wit
h a
sig
nif
ican
t d
ecre
ase i
n r
ate
of
Cae
sare
an d
eli
ver
y w
ith
n
o d
etecta
ble
in
crea
se i
n m
ater
nal
or
feta
l m
orb
idit
y.
NO
TE
S:
stu
dy
on
ly t
este
d 3
co
mp
on
ents
of
acti
ve m
gm
t (e
arly
am
nio
tom
y,
ear
ly d
iag
-n
osi
s o
f in
adeq
uat
e p
rog
ress
, an
d u
se o
f o
xy
-to
cin
at
hig
her
do
ses
than
usu
al);
stu
dy
was
u
nb
len
ded
, w
hic
h m
ay h
ave c
on
trib
ute
d t
o
low
er C
aesa
rean
rate
in
tra
dit
ion
al
mg
mt
gro
up
; st
ud
y d
iffe
rs f
rom
oth
er s
tud
ies
of
ac-
tiv
e m
anag
em
ent
in t
hat
pre
nata
l p
atie
nt
edu
cati
on
was
no
t in
clu
ded
, n
urs
e-m
idw
ives
wer
e n
ot
use
d t
o m
anag
e l
abo
r, a
nd
use
of
con
du
ctio
n a
nest
hesi
a w
as c
om
mo
n
Wo
rk G
rou
p’s
Co
mm
ents
: d
id s
am
ple
siz
e
esti
ma
tio
n t
o d
ete
rmin
e t
ha
t 7
00
pa
tien
ts
wo
uld
nee
d t
o b
e s
tud
ied
to
ach
ieve
a p
ow
er
of
80
% f
or
dete
cti
ng
a d
ecr
ease
in
th
e r
ate
o
f C
aes
are
an
deli
very
fro
m 1
8%
(ex
pect
ed
wit
h t
rad
itio
na
l m
an
ag
emen
t) t
o 1
1%
(w
ith
a
ctiv
e m
an
ag
emen
t)
Institute for Clinical Systems Improvement
www.icsi.org
50
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Bo
yla
n,
Fra
nk
ow
ski,
R
ou
ntr
ee,
Sel-
wy
n, &
Par
rish
(1
99
1)
No
n-
Ran
-d
om
/ H
is-
tori
cal
C
on
-tr
ols
C
ø
-3,9
00
bir
ths
to n
ull
ipar
ou
s w
om
en;
bef
ore
an
d a
fter
in
tro
- d
uct
ion
of
AM
L p
rog
ram
(tw
o
6-m
on
th p
erio
ds
in e
ach
ph
ase
) -E
lig
ible
pat
ien
ts h
ad v
erte
x
pre
sen
tati
on
, si
ng
leto
n p
reg
-n
ancy
, an
d n
o e
vid
ence
of
feta
l
dis
tres
s -D
efin
itiv
e d
iag
no
sis
of
lab
or
wit
hin
1 h
r o
f p
rese
nta
tio
n
-Att
end
ing
MD
s co
uld
ex
clu
de
pat
ien
ts f
rom
AM
L b
ut
all
pa-
tien
ts w
ere
incl
ud
ed i
n a
nal
ysi
s
-If
mem
bra
nes
had
no
t ru
ptu
red
wit
hin
2 h
rs o
f d
iag
no
sis,
art
ifi-
cial
ru
ptu
re w
as d
on
e -O
xy
toci
n w
as g
iven
if
cerv
ix
fail
ed t
o d
ilat
e at
>1
cm
/hr
-Ele
ctro
nic
fet
al h
ear
t ra
te
mo
nit
ori
ng
in
all
case
s -I
f n
o d
eliv
ery
im
min
ent
wit
hin
12
hrs
of
adm
issi
on
co
nsi
der
ed
do
ing
CS
; ep
idu
ral
anes
thes
ia
free
ly a
vail
able
-D
uri
ng
co
ntr
ol
per
iod
, m
anag
e-m
ent
was
wit
h e
xis
tin
g m
eth
od
s
-Def
ined
CS
as
du
e t
o d
yst
ocia
wh
en i
nd
icati
on
was
fa
ilu
re t
o p
rog
ress
or
cep
hal
op
elv
ic d
isp
rop
ort
ion
; al
so d
efin
ed C
S f
or
feta
l d
istr
ess,
bre
ech
pre
sen
ta-
tio
n a
nd
"o
ther
" -O
utc
om
es:
Co
ntr
ol
Per
iod
A
ML
Per
iod
(
1,8
43
bir
ths)
(2
,05
7 b
irth
s)
1
2
To
t.
1
2
To
t.
% C
aes
area
n
23
24
2
4
20
18
1
9
% D
yst
ocia
57
58
48
46
%
Fo
rcep
s
3
6
30
% S
po
nt.
Vag
inal
4
0
5
1
NO
TE
: 1
an
d 2
ref
er t
o 1
st 6
mo
s an
d 2
nd
6 m
os
-5.5
% d
rop
du
rin
g A
ML
per
iod
in
in
cid
ence
(p<
0.0
5)
of
CS
; 1
0%
red
uct
ion
in
in
cid
ence
of
dy
sto
cia
as a
n i
nd
icat
ion
fo
r C
S (
p<
0.0
5)
-33
% o
f th
ose
wit
h C
S f
or
dy
sto
cia
wer
e d
ue
to n
on-
com
pli
ance
wit
h A
ML
pro
toco
l; 3
2%
wer
e a
sso
ci-
ated
wit
h i
nd
uct
ion
of
lab
or
-No
dif
fere
nce
s b
etw
een
co
ntr
ol
and
AM
L p
erio
ds
for
ges
tati
on
an
d b
irth
weig
ht
-Co
ntr
ol:
1
in
trap
artu
m d
eath
, 1
neo
nata
l d
eath
, 3
6
adm
itte
d t
o N
ICU
, 8
neo
nata
l se
izu
re (
4.3
per
10
00
) -A
ML
: n
o i
ntr
apar
tum
deat
hs,
1 n
eon
atal
deat
h,
37
ad
mit
ted
to
NIC
U,
4 n
eon
ata
l se
izu
re (
1.9
per
10
00
) -G
reat
er d
ecr
eas
e am
on
g p
ati
ents
of
Un
iver
sity
fac
-u
lty
th
an p
atie
nts
fro
m H
MO
or
pri
vate
pra
cti
ce
-Th
e in
cid
ence
of
CS
fo
r in
dic
ati
on
of
dy
sto
cia
in n
ull
ipar
ou
s w
om
en m
ay b
e r
e-d
uce
d b
y A
ML
. N
OT
ES
: b
efo
re-a
fter
des
ign
can
no
t is
ola
te
the
effe
cts
of
specif
ic c
om
po
nen
ts o
f an
AM
L p
oli
cy
Wo
rk G
rou
p's
Co
mm
ents
: d
id s
am
ple
siz
e a
na
lysi
s to
dete
ct a
t le
ast
a 2
0%
rela
tive
de-
crea
se i
n i
nci
den
ce
of
CS
betw
een
co
ntr
ol
an
d i
nit
ial
AM
L p
erio
d w
ith
90
% p
ow
er a
t
p=
0.0
5
Institute for Clinical Systems Improvement
www.icsi.org
51
Conclusion Grading Worksheet B – Annotation #66 Management of Labor (Management of Protracted Labor) Third Edition/May 2009
Au
tho
r/Y
ear
D
esig
n
Ty
pe
Cla
ss
Qu
al-
ity
+
,–,ø
Po
pu
lati
on
Stu
die
d/S
am
ple
Siz
e P
rim
ary
Ou
tco
me M
eas
ure
(s)/
Res
ult
s (e
.g.,
p-v
alu
e,
con
fid
ence
inte
rval
, re
lati
ve r
isk
, o
dd
s ra
tio
, li
kel
i-h
oo
d r
atio
, n
um
ber
nee
ded
to
tre
at)
Au
tho
rs' C
on
clu
sio
ns/
W
ork
Gro
up
's C
om
men
ts (
ita
lici
zed
)
Tu
rner
, B
rass
il,
& G
ord
on
(1
98
8)
No
n-
Ran
-d
om
/ H
is-
tori
cal
C
on
-tr
ols
C
–
-10
00
co
nse
cuti
ve n
ull
ipar
ou
s w
om
en i
n l
abo
r af
ter
32
wk
s g
esta
tio
n w
ith
a c
eph
ali
c p
res-
enta
tio
n a
nd
a s
ing
le,
liv
e fe
tus;
la
bo
r co
nfi
rmed
-P
rog
ress
of
lab
or
mo
nit
ore
d b
y
vag
inal
asse
ssm
ent
ever
y 2
hrs
;
pro
gre
ss i
n 1
st s
tag
e m
eas
ure
d
by
cer
vic
al
dil
atat
ion
; p
rog
ress
in
2n
d s
tag
e m
easu
red
by
de-
scen
t o
f h
ead
; fa
ilu
re t
o p
rog
ress
tr
eate
d w
ith
ox
yto
cin
-L
abo
r in
du
ced
if
nece
ssar
y
-Ele
ctro
nic
fet
al h
ear
t ra
te
mo
nit
ori
ng
use
d r
ou
tin
ely
-D
ura
tio
n o
f la
bo
r w
as f
rom
ti
me
of
adm
issi
on
to
deli
ver
y
suit
e in
lab
or
-Mo
de
of
Deli
ver
y:
S
po
nta
neo
us
Lab
or
In
du
ced
Lab
or
T
ota
l
(
n=
61
4)
(n
=3
86
)
(n=
10
00
) N
orm
al
8
1%
7
1%
7
7%
L
ow
Cav
ity
Fo
rc. 1
3%
1
8%
1
5%
R
ota
tio
nal
Fo
rc.
3%
3
%
3
%
Caes
area
n
3
%
9
%
6
%
-2.5
% h
ad C
S f
or
dy
sto
cia;
3%
fo
r fe
tal
dis
tres
s;
0.3
% f
or
cep
halo
pelv
ic d
isp
rop
ort
ion
; 0
.2%
fo
r co
rd
pro
lap
se
-Th
ere
wer
e n
o C
S f
or
dy
sto
cia
aft
er s
po
nta
neo
us
on
set
of
lab
or;
13
aft
er i
nd
uced
lab
or
-O
xy
toci
n u
sed
du
rin
g 1
st s
tag
e fo
r 3
1%
an
d d
uri
ng
2
nd
sta
ge
for
13
%
-4%
wer
e in
lab
or
for
>1
2 h
rs
-No
in
trap
artu
m f
eta
l d
eath
s; 1
neo
nat
al d
eath
du
e t
o
con
gen
ital
hear
t le
sio
n;
1 d
eath
11
day
s p
ost
par
tum
d
ue
to p
erin
ata
l as
ph
yx
ia (
rela
ted
to
use
of
ox
yto
cin
d
esp
ite
feta
l d
istr
ess
); n
o n
eon
ata
l se
izu
res
-Co
mp
ared
to
data
fro
m p
rev
iou
s 4
year
s: fe
wer
CS
(p
<0
.05
); f
ewer
CS
fo
r d
yst
ocia
(p
<0
.05
); n
o i
n-
crea
ses
in p
erin
atal
mo
rtal
ity
-In
tro
du
ctio
n o
f ac
tiv
e m
anag
emen
t w
as a
s-so
ciat
ed w
ith
a 4
to
5%
red
uct
ion
in
CS
in
n
ull
ipar
ou
s w
om
en w
ith
no
ev
iden
ce
of
in-
crea
sed
per
inata
l m
ort
alit
y o
r m
orb
idit
y.
NO
TE
S:
co
mp
ared
dat
a fr
om
th
e s
tud
y p
e-
rio
d t
o d
ata
fro
m p
rev
iou
s 4
year
s –
th
e d
ata
fro
m t
he s
tud
y p
erio
d i
nclu
ded
data
fro
m p
a-ti
ents
wh
o w
ere
no
t act
ively
man
aged
(6
8%
o
f th
e d
eliv
erie
s d
uri
ng
th
e st
ud
y p
erio
d
wer
e to
wo
men
in
acti
ve
mg
mt
pro
toco
l)
Ak
ou
ry,
Bro
die
, C
add
ick
, M
cLau
gh
lin
, &
P
ug
h (
19
88
)
No
n-
Ran
-d
om
/ H
is-
tori
cal
Co
n-
tro
ls
C
–
-55
2 c
on
secu
tiv
e n
ull
ipar
ou
s w
om
en i
n s
po
nta
neo
us
lab
or
at
!3
7 w
ks
wit
h n
o f
eta
l d
istr
ess
on
ad
mis
sio
n;
lab
or
was
co
n-
firm
ed b
y o
bje
ctiv
e f
ind
ing
s
-Pro
gre
ss o
f la
bo
r m
on
ito
red
by
p
elv
ic e
xam
ev
ery
2 h
rs
-Ox
yto
cin
au
gm
enta
tio
n i
f ce
r-v
ix f
ail
ed t
o d
ilate
!1
cm
/hr
-Des
cen
t o
f h
ead
mo
nit
ore
d i
n
2n
d s
tag
e o
f la
bo
r -C
on
tin
uo
us
elec
tro
nic
feta
l
hea
rt r
ate
mo
nit
ori
ng
-D
ura
tio
n o
f la
bo
r w
as f
rom
w
hen
pati
ent
adm
itte
d h
erse
lf t
o
the
lab
or
suit
e
-His
tori
cal
co
ntr
ols
wer
e 5
33
nu
llip
aro
us
pat
ien
ts
adm
itte
d t
o t
he
sam
e fa
cil
ity
in
a s
imil
ar t
ime
per
iod
p
rio
r to
th
e s
tud
y p
erio
d;
char
ts w
ere r
evie
wed
wit
h
sam
e in
clu
sio
n/e
xclu
sio
n c
rite
ria a
s th
e st
ud
y g
rou
p
-Ou
tco
mes
(al
l p
<0
.00
5):
S
tud
y G
rou
p C
on
tro
l G
rou
p
Caes
area
n
2
4 (
4%
)
67
(1
3%
) F
orc
eps
del
iver
y
1
07
(1
9%
)
1
55
(2
9%
) L
abo
r >
12
hrs
3
7 (
7%
)
10
9 (
20
%)
-Per
inata
l o
utc
om
es (
AP
GA
R s
core
, N
ICU
ad
mis
-si
on
fo
r >
24
hrs
, h
yp
erb
ilir
ub
inem
ia,
meco
niu
m a
s-p
irat
ion
, ce
ph
alh
em
ato
ma,
seiz
ure
s an
d m
ort
alit
y)
wer
e co
mp
arab
le i
n b
oth
gro
up
s; u
se o
f ep
idu
ral
an-
alg
esi
a w
as c
om
par
able
(2
4%
in
stu
dy
gro
up
an
d
26
% i
n c
on
tro
l g
rou
p);
on
ly d
iffe
ren
ce w
as
in u
se o
f o
xy
toci
n (
41
% o
f st
ud
y g
rou
p a
nd
16
% o
f co
ntr
ol
gro
up
; p
<0
.00
5)
-Act
ive
man
agem
ent
of
lab
or
in n
ull
ipar
ou
s w
om
en r
edu
ced
th
e d
ura
tio
n o
f la
bo
r, t
he
use
of
forc
eps,
an
d t
he
rate
of
Cae
sare
an d
e-li
ver
ies
(CS
) w
ith
no
in
crea
se i
n p
erin
ata
l m
orb
idit
y a
nd
mo
rtali
ty.
52
I ICSI NSTITUTE FOR C LINICAL S YSTEMS I MPROVEMENT
Support for Implementation:
Management of Labor
Copyright © 2009 by Institute for Clinical Systems Improvement
This section provides resources, strategies and measurement specifications for use in closing the gap between current clinical practice and the recommendations set forth in the guideline.
The subdivisions of this section are:
• Priority Aims and Suggested Measures
- Measurement Specifications
• Key Implementation Recommendations
• Knowledge Resources
• Resources Available
Institute for Clinical Systems Improvement
www.icsi.org
53
Priority Aims and Suggested Measures
1. Increase the percentage of women with PTL and/or PTB who receive antenatal corticosteroids appro-priately.
Possible measures of accomplishing this aim:
a. Percentage of mothers with PTL who were given appropriate antenatal corticosteroids during labor.
b. Percentage of mothers with PTB who were given appropriate antenatal corticosteroids during labor.
2. Prevent unnecessary protracted labor with use of Management of Labor Dystocia algorithm and annota-tions and its methods.
Possible measure of accomplishing this aim:
a. Percent of women whose time from admission with active labor to evaluation of labor's progress is less than two hours.
3. Increase the use of procedures that assist in progress to vaginal birth.
Possible measures of accomplishing this aim:
a. Percent of women in the guideline population who have SROM or early amniotomy.
b. Percent of women in the guideline population with failure to progress diagnosis who have oxytocin.
4. Increase the percentage of women who are assessed for risk status on entry to labor and delivery.
Possible measure of accomplishing this aim:
a. Percentage of women who are assessed for risk status on entry to labor and delivery.
5. Increase the use of remedial techniques that resolve temporary abnormal fetal heart tracing in labor.
Possible measures of accomplishing this aim:
a. Among those who had begun oxytocin and with abnormal FHR tracing, the percentage of births with discontinuance of oxytocin.
b. Percentage of births with amnioinfusion when any of the following is present: thick meconium, repetitive severe variable decelerations or oligohydramnios.
6. Perform an appropriate evaluation for persistent abnormal heart rate tracing in labor before Caesarean.
Possible measures of accomplishing this aim:
a. Percentage of births with either scalp stimulation, scalp pH or vibroacoustic stimulation of those births with intervention for abnormal FHR tracing.
b. Percentage of Caesarean deliveries.
Management of Labor Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
54
Measurement Specifications
Possible Success Measure # 3a Percent of women in the guideline population who have SROM or early amniotomy.
Population Definition All women giving birth who are:
• full term (36 completed weeks),• nullipara,• without concomitant medical problems,• having contractions,• singleton fetus,• cephalic presentation,• no evidence of fetal distress, and• expected to have a normal spontaneous vaginal delivery.
Data of Interest # among the denominator with either SROM or early amniotomy
# of women giving birth included in the population definition above
Numerator/Denominator Definitions Numerator: All births among denominator with no intact membrane at beginning of active labor. This is accomplished either by either SROM or amniotomy.
Denominator: All births by women who are covered in the guideline as described by: nullipara female, without concomitant medical problems, at term pregnancy (36 completed weeks), having contractions, singleton fetus, cephalic presentation, no evidence of fetal distress, expected normal spontaneous vaginal delivery.
Method/Source of Data Collection Any one of several possible data collection methods may be used by the medical group to capture data for this particular population.
1. Data may be obtained retrospectively by a chart audit (using a minimum sample of 20 charts per month).
2. Data may be obtained through discharge abstract coding or other data base from the hospital.
3. The hospital may send the medical group a copy of the labor and delivery summary sheet for deliv-eries.
4. A copy of the nursing checklist form is sent to the medical group for data collection.
Data are reviewed to determine if the delivery fits the inclusion criteria for the measure. If no, the birth is not reviewed. If yes, the birth data are reviewed to assess if amniotomy or SROM occurred and whether oxytocin was used.
Management of Labor Priority Aims and Suggested Measures Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
55
Time Frame Pertaining to Data Collection It is suggested that these data are collected monthly.
Notes This is the rate where the membrane is not present in active labor. The absence of membranes at the begin-ning of labor helps progress to vaginal birth. This rate should increase.
Management of Labor Priority Aims and Suggested Measures Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
56
Possible Success Measure #3b Percent of women in the guideline population with failure to progress diagnosis who have oxytocin.
Population Definition All women giving birth who are:
• full term (36 completed weeks), • nullipara,• without concomitant medical problems, • having contractions,• singleton fetus,• cephalic presentation, • no evidence of fetal distress, and • expected to have a normal spontaneous vaginal delivery.
Data of Interest # of births with oxytocin among the denominator
# of births to guideline women with failure to progress diagnosis
Numerator/Denominator Definitions Numerator: # of births of denominator where oxytocin is used.
Denominator: # of births to women covered in the guideline as described by: nullipara female, without concomitant medical problems, at term pregnancy (36 completed), having contractions, singleton fetus, cephalic presentation, no evidence of fetal distress, expected normal spontaneous vaginal delivery and diagnosis of failure to progress.
Method/Source of Data Collection Any one of several possible data collection methods may be used by the medical group to capture data for this particular population.
1. Data may be obtained retrospectively by a chart audit (using a minimum sample of 20 charts per month).
2. Data may be obtained through discharge abstract coding or other data base from the hospital. Then the hospital can relay data for a medical group's deliveries.
3. The hospital may send the medical group a copy of the labor and delivery summary sheet for deliv-eries.
4. A copy of the nursing checklist form is sent to the medical group for data collection.
Data are reviewed to determine if the delivery fits the inclusion criteria for the measure. If no, the birth is not reviewed. If yes, the birth data are reviewed to assess if amniotomy or SROM occurred and whether oxytocin was used.
Time Frame Pertaining to Data Collection It is suggested that these data are collected monthly.
Management of Labor Priority Aims and Suggested Measures Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
57
Possible Success Measure #4a Percentage of women who are assessed for risk status on entry to labor and delivery.
Population Definition All women who present in labor.
Data of Interest # of women who are assessed for risk status on entry to labor and delivery
total # of women whose medical records are reviewed
Numerator/Denominator Definitions Numerator: # of women with evidence of assessment for risk status on entry to labor and delivery to include:
• 20-minute fetal heart rate (FHR) assessment,• patient assessment,• prenatal risk review, and• risk in labor assessment.
Denominator: # of women who present in labor.
Method/Source of Data Collection Any one of several possible data collection methods may be used by the medical group to capture data for this population.
1. Data may be obtained retrospectively by a chart audit (using a minimum sample of 20 charts per month) of all women presenting in labor.
2. Data may be obtained through discharge abstract coding or other data base from the hospital.
3. The hospital may send the medical group a copy of the labor and delivery summary sheet.
Time Frame Pertaining to Data Collection Suggested time frame for data collection is monthly.
Notes Risk assessment should be performed on all patients in active labor and is the responsibility of all members of the health care team. That includes, but is not limited to nurses, midwives and physicians.
Management of Labor Priority Aims and Suggested Measures Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
58
Possible Success Measure #5b Percentage of births with amnioinfusion when either of the following is present: thick meconium or repeti-tive severe variable decelerations or oligohydramnios.
Data of Interest # of women who have amnioinfusion
# of women giving birth who have one or more of the following present: thick meconium and repetitive severe variable decelerations and/or prolonged decelerations
Numerator/Denominator Definitions Numerator: # of eligible births with amnioinfusion.
Denominator: # of births having one or more of the following present: thick meconium, repetitive severe variable decelerations or oligohydramnios. In the case of multiple births at a delivery, the birth event is counted once.
Method/Source of Data Collection Any one of several possible data collection methods may be used by the medical group to capture data for this population.
1. Data may be obtained retrospectively by a chart audit (using a minimum sample of 20 charts per month as defined by denominator above.)
2. Data may be obtained through discharge abstract coding or other data base from the hospital.
3. The hospital may send the medical group a copy of the labor and delivery summary sheet.
4. A copy of the nursing checklist form is send to the medical group for data collection.
Data are reviewed to determine if the delivery fits the inclusion criteria for the measure. If no, the birth is not reviewed. If yes, the birth data are reviewed to assess whether an amnioinfusion was performed.
Time Frame Pertaining to Data Collection These data will be collected monthly.
Notes Amnioinfusion for fetal stress may be performed if operative delivery is contemplated. It is expected that the amnioinfusion rate will increase.
Management of Labor Priority Aims and Suggested Measures Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
59
Knowledge Resources
Criteria for Selecting ResourcesThe following resources were selected by the Management of Labor guideline work group as addi-tional resources for providers and/or patients. The following criteria were considered in selecting these resources.
• The site contains information specific to the topic of the guideline.
• The content is supported by evidence-based research.
• The content includes the source/author and contact information.
• The content clearly states revision dates or the date the information was published.
• The content is clear about potential biases, noting conflict of interest and/or disclaimers as appropriate.
Resources Available to ICSI Members OnlyICSI has a wide variety of knowledge resources that are only available to ICSI members (these are indicated with an asterisk in far left-hand column of the Resources Available table). In addition to the resources listed in the table, ICSI members have access to a broad range of materials including tool kits on CQI processes and Rapid Cycling that can be helpful. To obtain copies of these or other Knowledge Resources, go to http://www.icsi.org/improvement_resources. To access these materials on the Web site, you must be logged in as an ICSI member.
The resources in the table on the next page that are not reserved for ICSI members are available to the public free-of-charge.
Management of Labor Third Edition/May 2009
Institute for Clinical Systems Improvement
www.icsi.org
60
* Author/Organization Title/Description Audience Web Sites/Order InformationAmerican College of Obstetricians & Gynecologists (ACOG)
Preterm Labor (pamphlet 1999) Public 1-800-762-2264 AP087
American College of Obstetricians & Gynecologists (ACOG)
OB/GYN topics Professionals http://www.acog.org
American College of Obstetricians & Gynecologists (ACOG)
Vaginal Birth After Caesarean (pamphlet)
Public 1-800-762-2264 #AP070
American College of Obstetricians & Gynecologists (ACOG)
Fetal Heart Rate Monitoring During Labor (pamphlet)
Public 1-800-762-2264 x830; #18015
March of Dimes Includes downloadable fact sheets on a wide variety of topics related to healthy pregnancy and delivery of healthy babies. Fact sheets include prenatal nutrition, healthy lifestyle before, during and after pregnancy, and prevention of birth defects. Q & A option.
Public &Professionals
http://www.marchofdimes.com
Toll-free number also available for direct contact with the March of Dimes: 1-888-MODIMES (663-4637)
March of Dimes Preventing Preterm Labor Public 1-800-367-6630 #09-754-00
March of Dimes Premature Labor: A Teaching Guide Public 1-800-367-6630 English #33-205-03 Spanish #33-205-04
March of Dimes Learn the Signs of Preterm Labor (flyer)
Public 1-800-367-6630 English #09-1099-98; Spanish #09-1100-98
Mayo Clinic Includes alphabetical listings of con-ditions as well as search capabilities for information on specific areas of health care including many aspects of prenatal care.
Public http://www.mayoclinic.com
National Women's Health Informa-tion Center/Office of Women's Health, U.S. Dept. of Health and Human Services
Provides information on many preg-nancy-related topics including nutrition and fitness, prevention of birth defects and complications of pregnancy, and financial assistance. Also provides information on preparing for childbirth and tips on caring for a newborn. In English and Spanish.
Public http://www.womanshealth.gov/ pregnancy
Call 1-800-994-Woman (1-800-994-9662) or 1-888-220-5546 for the hearing impaired.
Resources Available
Management of Labor Third Edition/May 2009
* Available to ICSI members only.